Ronald van Vollenhoven

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: ARTHRITIS CARE & RESEARCH. 2020;72(12):1800-1808

Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach.

Barber MRW; Hanly JG; Su L; Urowitz MB; St Pierre Y; Romero-Diaz J; Gordon C; Bae S-C; Bernatsky S; Wallace DJ; Merrill JT; Isenberg DA; Rahman A; Ginzler EM; Petri M; Bruce IN; Dooley MA; Fortin PR; Gladman DD; Sanchez-Guerrero J; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Mackay M; Alarcón GS; Manzi S; Nived O; Jönsen A; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Farewell V; Stoll T; Buyon J; Clarke AE
Article: ARTHRITIS & RHEUMATOLOGY. 2020;72(4):658-666

Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index.

Legge A; Kirkland S; Rockwood K; Andreou P; Bae S-C; Gordon C; Romero-Diaz J; Sanchez-Guerrero J; Wallace DJ; Bernatsky S; Clarke AE; Merrill JT; Ginzler EM; Fortin PR; Gladman DD; Urowitz MB; Bruce IN; Isenberg DA; Rahman A; Alarcón GS; Petri M; Khamashta MA; Dooley MA; Ramsey-Goldman R; Manzi S; Zoma AA; Aranow C; Mackay M; Ruiz-Irastorza G; Lim SS; Inanc M; van Vollenhoven RF; Jonsen A; Nived O; Ramos-Casals M; Kamen DL; Kalunian KC; Jacobsen S; Peschken CA; Askanase A; Hanly JG
Article: ANNALS OF THE RHEUMATIC DISEASES. 2020;79(3):356-362

Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach.

Hanly JG; Urowitz MB; Gordon C; Bae S-C; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Ramsey-Goldman R; Manzi S; Jönsen A; Alarcón GS; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Lim S; Inanc M; Kalunian KC; Jacobsen S; Peschken CA; Kamen DL; Askanase A; Farewell V
Article: JOURNAL OF AUTOIMMUNITY. 2020;106:102340

Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.

Enocsson H; Wirestam L; Dahle C; Padyukov L; Jönsen A; Urowitz MB; Gladman DD; Romero-Diaz J; Bae S-C; Fortin PR; Sanchez-Guerrero J; Clarke AE; Bernatsky S; Gordon C; Hanly JG; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Ginzler E; Alarcón GS; Chatham WW; Petri M; Khamashta M; Aranow C; Mackay M; Dooley MA; Manzi S; Ramsey-Goldman R; Nived O; Steinsson K; Zoma AA; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; van Vollenhoven RF; Ramos-Casals M; Kamen DL; Jacobsen S; Peschken CA; Askanase A; Stoll T; Bruce IN; Wetterö J; Sjöwall C
Article: ARTHRITIS & RHEUMATOLOGY. 2020;72(1):67-77

Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Hanly JG; Li Q; Su L; Urowitz MB; Gordon C; Bae S-C; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Steinsson K; Ramsey-Goldman R; Zoma AA; Manzi S; Nived O; Jonsen A; Khamashta MA; Alarcón GS; Svenungsson E; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Ramos-Casals M; Lim SS; Inanc M; Kalunian KC; Jacobsen S; Peschken CA; Kamen DL; Askanase A; Theriault C; Farewell V
Article: JOURNAL OF RHEUMATOLOGY. 2020;47(1):72-81

Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus.

Legge A; Kirkland S; Rockwood K; Andreou P; Bae S-C; Gordon C; Romero-Diaz J; Sanchez-Guerrero J; Wallace DJ; Bernatsky S; Clarke AE; Merrill JT; Ginzler EM; Fortin P; Gladman DD; Urowitz MB; Bruce IN; Isenberg DA; Rahman A; Alarcón GS; Petri M; Khamashta MA; Dooley MA; Ramsey-Goldman R; Manzi S; Zoma AA; Aranow C; Mackay M; Ruiz-Irastorza G; Lim SS; Inanc M; van Vollenhoven RF; Jonsen A; Nived O; Ramos-Casals M; Kamen DL; Kalunian KC; Jacobsen S; Peschken CA; Askanase A; Hanly JG
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2019;48(5):362-366

Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population.

Hambardzumyan K; Hermanrud C; Marits P; Vivar N; Ernestam S; Wallman JK; van Vollenhoven RF; Fogdell-Hahn A; Saevarsdottir S; SWEFOT study group
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2019;106(2):374-382

A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires.

Costedoat-Chalumeau N; Houssiau F; Izmirly P; Guern VL; Navarra S; Jolly M; Ruiz-Irastorza G; Baron G; Hachulla E; Agmon-Levin N; Shoenfeld Y; Dall'Ara F; Buyon J; Deligny C; Cervera R; Lazaro E; Bezanahary H; Leroux G; Morel N; Viallard J-F; Pineau C; Galicier L; Vollenhoven RV; Tincani A; Nguyen H; Gondran G; Zahr N; Pouchot J; Piette J-C; Petri M; Isenberg D
Article: ARTHRITIS & RHEUMATOLOGY. 2019;71(8):1297-1307

Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus.

Legge A; Kirkland S; Rockwood K; Andreou P; Bae S-C; Gordon C; Romero-Diaz J; Sanchez-Guerrero J; Wallace DJ; Bernatsky S; Clarke AE; Merrill JT; Ginzler EM; Fortin P; Gladman DD; Urowitz MB; Bruce IN; Isenberg DA; Rahman A; Alarcón GS; Petri M; Khamashta MA; Dooley MA; Ramsey-Goldman R; Manzi S; Steinsson K; Zoma AA; Aranow C; Mackay M; Ruiz-Irastorza G; Lim SS; Inanc M; van Vollenhoven RF; Jonsen A; Nived O; Ramos-Casals M; Kamen DL; Kalunian KC; Jacobsen S; Peschken CA; Askanase A; Hanly JG
Article: ARTHRITIS CARE & RESEARCH. 2019;71(7):893-902

Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort.

Choi MY; Clarke AE; St Pierre Y; Hanly JG; Urowitz MB; Romero-Diaz J; Gordon C; Bae S-C; Bernatsky S; Wallace DJ; Merrill JT; Isenberg DA; Rahman A; Ginzler EM; Petri M; Bruce IN; Dooley MA; Fortin PR; Gladman DD; Sanchez-Guerrero J; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Alarcón GS; Manzi S; Nived O; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Stoll T; Buyon J; Mahler M; Fritzler MJ
Article: RHEUMATOLOGY. 2019;58(7):1259-1267

Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen.

Mendel A; Bernatsky S; Pineau CA; St-Pierre Y; Hanly JG; Urowitz MB; Clarke AE; Romero-Diaz J; Gordon C; Bae S-C; Wallace DJ; Merrill JT; Buyon J; Isenberg DA; Rahman A; Ginzler EM; Petri M; Dooley MA; Fortin P; Gladman DD; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Mackay M; Alarcón G; Manzi S; Nived O; Jönsen A; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim S; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Sanchez-Guerrero J; Bruce IN; Costedoat-Chalumeau N; Vinet E
Article: JOURNAL OF RHEUMATOLOGY. 2019;46(6):555-563

Serum Biomarkers for Prediction of Response to Methotrexate Monotherapy in Early Rheumatoid Arthritis: Results from the SWEFOT Trial.

Hambardzumyan K; Bolce RJ; Wallman JK; van Vollenhoven RF; Saevarsdottir S
Article: JOURNAL OF RHEUMATOLOGY. 2019;46(5):492-500

Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.

Wirestam L; Enocsson H; Skogh T; Padyukov L; Jönsen A; Urowitz MB; Gladman DD; Romero-Diaz J; Bae S-C; Fortin PR; Sanchez-Guerrero J; Clarke AE; Bernatsky S; Gordon C; Hanly JG; Wallace D; Isenberg DA; Rahman A; Merrill J; Ginzler E; Alarcón GS; Chatham WW; Petri M; Khamashta M; Aranow C; Mackay M; Dooley MA; Manzi S; Ramsey-Goldman R; Nived O; Steinsson K; Zoma A; Ruiz-Irastorza G; Lim S; Kalunian K; Inanc M; van Vollenhoven R; Ramos-Casals M; Kamen DL; Jacobsen S; Peschken C; Askanase A; Stoll T; Bruce IN; Wetterö J; Sjöwall C
Article: EXPERT OPINION ON BIOLOGICAL THERAPY. 2019;19(2):157-168

Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies.

Parodis I; Emamikia S; Gomez A; Gunnarsson I; van Vollenhoven RF; Chatzidionysiou K
Article: ARTHRITIS & RHEUMATOLOGY. 2019;71(2):281-289

Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Hanly JG; Li Q; Su L; Urowitz MB; Gordon C; Bae S-C; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Steinsson K; Ramsey-Goldman R; Zoma AA; Manzi S; Nived O; Jonsen A; Khamashta MA; Alarcón GS; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Ramos-Casals M; Lim SS; Inanc M; Kalunian KC; Jacobsen S; Peschken CA; Kamen DL; Askanase A; Theriault C; Farewell V
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2019;48(1):17-23

Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration.

Chatzidionysiou K; Lukina G; Gabay C; Hetland ML; Hauge EM; Pavelka K; Nordström D; Canhão H; Tomsic M; Rotar Z; Lie E; Kvien TK; van Vollenhoven RF; Saevarsdottir S
Article: JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS. 2019;42(1):34-46

Joint Mobilization of the Hands of Patients With Rheumatoid Arthritis: Results From an Assessor-Blinded, Randomized Crossover Trial.

Levitsky A; Kisten Y; Lind S; Nordström P; Hultholm H; Lyander J; Hammelin V; Gentline C; Giannakou I; Faustini F; Skillgate E; van Vollenhoven R; Sundberg T
Article: ARTHRITIS CARE & RESEARCH. 2018;70(10):1478-1487

Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Hanly JG; Li Q; Su L; Urowitz MB; Gordon C; Bae S-C; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin P; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Steinsson K; Ramsey-Goldman R; Zoma AA; Manzi S; Nived O; Jonsen A; Khamashta MA; Alarcón GS; Chatham W; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Ramos-Casals M; Lim SS; Inanc M; Kalunian KC; Jacobsen S; Peschken CA; Kamen DL; Askanase A; Theriault C; Farewell V
Article: ARTHRITIS CARE & RESEARCH. 2018;70(9):1294-1302

Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach.

Barber MRW; Hanly JG; Su L; Urowitz MB; St Pierre Y; Romero-Diaz J; Gordon C; Bae S-C; Bernatsky S; Wallace DJ; Isenberg DA; Rahman A; Ginzler EM; Petri M; Bruce IN; Fortin PR; Gladman DD; Sanchez-Guerrero J; Ramsey-Goldman R; Khamashta MA; Aranow C; Mackay M; Alarcón GS; Manzi S; Nived O; Jönsen A; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Theriault C; Farewell V; Clarke AE
Article: LUPUS. 2018;27(9):1470-1478

Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL.

Parodis I; Söder F; Faustini F; Kasza Z; Samuelsson I; Zickert A; Svenungsson E; van Vollenhoven RF; Malmström V; Wermeling F; Gunnarsson I
Article: PHARMACOGENOMICS JOURNAL. 2018;18(4):528-538

Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients.

Taylor JC; Bongartz T; Massey J; Mifsud B; Spiliopoulou A; Scott IC; Wang J; Morgan M; Plant D; Colombo M; Orchard P; Twigg S; McInnes IB; Porter D; Freeston JE; Nam JL; Cordell HJ; Isaacs JD; Strathdee JL; Arnett D; de Hair MJH; Tak PP; Aslibekyan S; van Vollenhoven RF; Padyukov L; Bridges SL; Pitzalis C; Cope AP; Verstappen SMM; Emery P; Barnes MR; Agakov F; McKeigue P; Mushiroda T; Kubo M; Weinshilboum R; Barton A; Morgan AW; Barrett JH; MATURA; and PAMERA; Consortia
Article: INTERNATIONAL JOURNAL OF RHEUMATOLOGY. 2018;2018:9152480-7

Long-Term Dietary Changes after Diagnosis of Rheumatoid Arthritis in Swedish Women: Data from a Population-Based Cohort.

Lourdudoss C; Arnaud L; Wolk A; van Vollenhoven RF; Di Giuseppe D
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2018;103(6):1074-1082

A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires.

Costedoat-Chalumeau N; Houssiau F; Izmirly P; Le Guern V; Navarra S; Jolly M; Ruiz-Irastorza G; Baron G; Hachulla E; Agmon-Levin N; Shoenfeld Y; Dall'Ara F; Buyon J; Deligny C; Cervera R; Lazaro E; Bezanahary H; Leroux G; Morel N; Viallard J-F; Pineau C; Galicier L; Van Vollenhoven R; Tincani A; Nguyen H; Gondran G; Zahr N; Pouchot J; Piette J-C; Petri M; Isenberg D
Article: RHEUMATOLOGY. 2018;57(4):677-687

Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort.

Little J; Parker B; Lunt M; Hanly JG; Urowitz MB; Clarke AE; Romero-Diaz J; Gordon C; Bae S-C; Bernatsky S; Wallace DJ; Merrill JT; Buyon J; Isenberg DA; Rahman A; Ginzler EM; Petri M; Dooley MA; Fortin P; Gladman DD; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Mackay M; Alarcón GS; Manzi S; Nived O; Jönsen A; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Sam Lim S; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Sanchez-Guerrero J; Bruce IN
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2018;47(2):131-140

Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial.

Emamikia S; Gentline C; Chatzidionysiou K; Arnaud L; van Vollenhoven R
Article: ARTHRITIS CARE & RESEARCH. 2018;70(2):205-212

Dietary Intake of Polyunsaturated Fatty Acids and Pain in Spite of Inflammatory Control Among Methotrexate-Treated Early Rheumatoid Arthritis Patients.

Lourdudoss C; Di Giuseppe D; Wolk A; Westerlind H; Klareskog L; Alfredsson L; van Vollenhoven RF; Lampa J
Article: LUPUS SCIENCE & MEDICINE. 2018;5(1):e000287

Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort.

Giannakou I; Chatzidionysiou K; Magder LS; Györi N; van Vollenhoven R; Petri MA
Article: ARTHRITIS CARE & RESEARCH. 2018;70(1):98-103

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients.

Isenberg D; Sturgess J; Allen E; Aranow C; Askanase A; Sang-Cheol B; Bernatsky S; Bruce I; Buyon J; Cervera R; Clarke A; Dooley MA; Fortin P; Ginzler E; Gladman D; Hanly J; Inanc M; Jacobsen S; Kamen D; Khamashta M; Lim S; Manzi S; Nived O; Peschken C; Petri M; Kalunian K; Rahman A; Ramsey-Goldman R; Romero-Diaz J; Ruiz-Irastorza G; Sanchez-Guerrero J; Steinsson K; Sturfelt G; Urowitz M; van Vollenhoven R; Wallace DJ; Zoma A; Merrill J; Gordon C
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2018;36(1):21-28

Rheumatologists' guideline adherence in rheumatoid arthritis: a randomised controlled study on electronic decision support, education and feedback.

Lesuis N; van Vollenhoven RF; Akkermans RP; Verhoef LM; Hulscher ME; den Broeder AA
Article: ARTHRITIS RESEARCH & THERAPY. 2017;19(1):287

Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study.

Ferreira I; Croca S; Raimondo MG; Matharu M; Miller S; Giles I; Isenberg D; Ioannou Y; Hanly JG; Urowitz MB; Anderson N; Aranow C; Askanase A; Bae S-C; Bernatsky S; Bruce IN; Buyon J; Clarke AE; Dooley MA; Fortin P; Ginzler E; Gladman D; Gordon C; Inanc M; Jacobsen S; Kalunian K; Kamen D; Khamashta M; Lim S; Manzi S; Merrill J; Nived O; Peschken C; Petri M; Ramsey-Goldman R; Ruiz-Irastorza G; Sanchez-Guerrero J; Steinson K; Sturfelt GK; van Vollenhoven R; Wallace DJ; Zoma A; Rahman A
Article: LUPUS. 2017;26(10):1051-1059

The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients.

Choi MY; Clarke AE; St Pierre Y; Hanly JG; Urowitz MB; Romero-Diaz J; Gordon C; Bae S-C; Bernatsky S; Wallace DJ; Merrill JT; Isenberg DA; Rahman A; Ginzler EM; Petri M; Bruce IN; Dooley MA; Fortin P; Gladman DD; Sanchez-Guerrero J; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Alarcón GS; Manzi S; Nived O; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Buyon J; Mahler M; Fritzler MJ
Article: ARTHRITIS & RHEUMATOLOGY. 2017;69(9):1751-1761

Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis.

Genovese MC; Kremer JM; van Vollenhoven RF; Alten R; Scali JJ; Kelman A; Dimonaco S; Brockwell L
Article: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(7):1279-1284

Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.

Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
Article: BMJ OPEN. 2017;7(6):e016154

Are dietary vitamin D, omega-3 fatty acids and folate associated with treatment results in patients with early rheumatoid arthritis? Data from a Swedish population-based prospective study.

Lourdudoss C; Wolk A; Nise L; Alfredsson L; Vollenhoven RV
Article: RHEUMATOLOGY AND THERAPY. 2017;4(1):57-69

Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients.

Fleischmann R; van Vollenhoven RF; Vencovský J; Alten R; Davies O; Mountian I; de Longueville M; Carter D; Choy E
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2017;46(3):241-246

Choosing wisely in daily practice: a mixed methods study on determinants of antinuclear antibody testing by rheumatologists.

Lesuis N; den Broeder AA; van Vollenhoven RF; Vriezekolk JE; Hulscher M
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2017;35(3):379-383

The effects of an educational meeting and subsequent computer reminders on the ordering of laboratory tests by rheumatologists: an interrupted time series analysis.

Lesuis N; den Broeder N; Boers N; Piek E; Teerenstra S; Hulscher M; van Vollenhoven R; den Broeder AA
Article: ARTHRITIS & RHEUMATOLOGY. 2017;69(5):953-963

A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.

Hambardzumyan K; Saevarsdottir S; Forslind K; Petersson IF; Wallman JK; Ernestam S; Bolce RJ; van Vollenhoven RF
Article: TRIALS. 2017;18(1):161

Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study.

Glinatsi D; Heiberg MS; Rudin A; Nordström D; Haavardsholm EA; Gudbjornsson B; Østergaard M; Uhlig T; Grondal G; Hørslev-Petersen K; van Vollenhoven R; Hetland ML
Article: RHEUMATOLOGY. 2017;56(4):541-549

Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.

Moots RJ; Sebba A; Rigby W; Ostor A; Porter-Brown B; Donaldson F; Dimonaco S; Rubbert-Roth A; van Vollenhoven R; Genovese MC
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2017;46(2):152-155

Implementation of protocolized tight control and biological dose optimization in daily clinical practice: results of a pilot study.

Lesuis N; Verhoef LM; Nieboer LM; Bruyn GA; Baudoin P; van Vollenhoven RF; Hulscher M; van den Hoogen F; den Broeder AA
Article: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(3):554-561

A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).

van Vollenhoven R; Voskuyl A; Bertsias G; Aranow C; Aringer M; Arnaud L; Askanase A; Balážová P; Bonfa E; Bootsma H; Boumpas D; Bruce I; Cervera R; Clarke A; Coney C; Costedoat-Chalumeau N; Czirják L; Derksen R; Doria A; Dörner T; Fischer-Betz R; Fritsch-Stork R; Gordon C; Graninger W; Györi N; Houssiau F; Isenberg D; Jacobsen S; Jayne D; Kuhn A; Le Guern V; Lerstrøm K; Levy R; Machado-Ribeiro F; Mariette X; Missaykeh J; Morand E; Mosca M; Inanc M; Navarra S; Neumann I; Olesinska M; Petri M; Rahman A; Rekvig OP; Rovensky J; Shoenfeld Y; Smolen J; Tincani A; Urowitz M; van Leeuw B; Vasconcelos C; Voss A; Werth VP; Zakharova H; Zoma A; Schneider M; Ward M
Article: JOURNAL OF RHEUMATOLOGY. 2017;44(2):162-169

Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration.

Chatzidionysiou K; Lie E; Lukina G; Hetland ML; Hauge E-M; Pavelka K; Gabay C; Scherer A; Nordström D; Canhao H; Santos MJ; Tomsic M; Rotar Z; Hernández MV; Gomez-Reino J; Ancuta I; Kvien TK; van Vollenhoven R
Article: LUPUS SCIENCE & MEDICINE. 2017;4(1):e000192

Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort.

Györi N; Giannakou I; Chatzidionysiou K; Magder L; van Vollenhoven RF; Petri M
Article: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(1):126-132

Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists.

Hifinger M; Hiligsmann M; Ramiro S; Watson V; Severens JL; Fautrel B; Uhlig T; van Vollenhoven R; Jacques P; Detert J; Canas da Silva J; Scirè CA; Berghea F; Carmona L; Péntek M; Keat A; Boonen A
Article: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(1):96-104

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.

Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
Article: RMD OPEN. 2017;3(1):e000371

Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis.

Fleischmann R; Tongbram V; van Vollenhoven R; Tang DH; Chung J; Collier D; Urs S; Ndirangu K; Wells G; Pope J
Article: RMD OPEN. 2017;3(2):e000458

Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial.

Levitsky A; Brismar K; Hafström I; Hambardzumyan K; Lourdudoss C; van Vollenhoven RF; Saevarsdottir S
Article: RMD OPEN. 2017;3(1):e000369

Fully automated joint space width measurement and digital X-ray radiogrammetry in early RA.

Platten M; Kisten Y; Kälvesten J; Arnaud L; Forslind K; van Vollenhoven R
Article: LUPUS. 2016;25(14):1602-1609

Dietary micronutrient intake and atherosclerosis in systemic lupus erythematosus.

Lourdudoss C; Elkan A-C; Hafström I; Jogestrand T; Gustafsson T; van Vollenhoven R; Frostegård J
Article: ARTHRITIS CARE & RESEARCH. 2016;68(12):1758-1766

Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial.

Eriksson JK; Wallman JK; Miller H; Petersson IF; Ernestam S; Vivar N; van Vollenhoven RF; Neovius M
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(11):1939-1944

Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study.

Kievit W; van Herwaarden N; van den Hoogen FH; van Vollenhoven RF; Bijlsma JW; van den Bemt BJ; van der Maas A; den Broeder AA
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2016;34(6):1065-1071

Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials.

Levitsky A; Wick MC; Möttönen T; Leirisalo-Repo M; Laasonen L; Korpela M; van Vollenhoven RF; Rantalaiho V
Article: LUPUS. 2016;25(13):1420-1430

Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus.

Kahl L; Patel J; Layton M; Binks M; Hicks K; Leon G; Hachulla E; Machado D; Staumont-Sallé D; Dickson M; Condreay L; Schifano L; Zamuner S; van Vollenhoven RF; JAK115919 Study Team
Article: ARTHRITIS & RHEUMATOLOGY. 2016;68(9):2174-2183

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.

Rovin BH; van Vollenhoven RF; Aranow C; Wagner C; Gordon R; Zhuang Y; Belkowski S; Hsu B
Article: ARTHRITIS & RHEUMATOLOGY. 2016;68(8):1932-1944

A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach.

Hanly JG; Su L; Urowitz MB; Romero-Diaz J; Gordon C; Bae S-C; Bernatsky S; Clarke AE; Wallace DJ; Merrill JT; Isenberg DA; Rahman A; Ginzler EM; Petri M; Bruce IN; Dooley MA; Fortin P; Gladman DD; Sanchez-Guerrero J; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Alarcón GS; Fessler BJ; Manzi S; Nived O; Sturfelt GK; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Theriault C; Farewell V
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(7):1336-1342

Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study.

Gabay C; Riek M; Hetland ML; Hauge E-M; Pavelka K; Tomšič M; Canhao H; Chatzidionysiou K; Lukina G; Nordström DC; Lie E; Ancuta I; Hernández MV; van Riel PLMC; van Vollenhoven R; Kvien TK
Article: ARTHRITIS RESEARCH & THERAPY. 2016;18:145

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.

Genovese MC; van Vollenhoven RF; Wilkinson B; Wang L; Zwillich SH; Gruben D; Biswas P; Riese R; Takiya L; Jones TV
Article: NATURE REVIEWS DISEASE PRIMERS. 2016;2:16039

Systemic lupus erythematosus.

Kaul A; Gordon C; Crow MK; Touma Z; Urowitz MB; van Vollenhoven R; Ruiz-Irastorza G; Hughes G
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(6):1081-1091

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.

Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Kelman A; Dimonaco S; Mitchell N
Article: LUPUS. 2016;25(7):699-709

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care.

Bruce IN; Urowitz M; van Vollenhoven R; Aranow C; Fettiplace J; Oldham M; Wilson B; Molta C; Roth D; Gordon D
Article: RHEUMATOLOGY. 2016;55(6):1031-1041

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.

Strand V; van Vollenhoven RF; Lee EB; Fleischmann R; Zwillich SH; Gruben D; Koncz T; Wilkinson B; Wallenstein G
Article: PRESSE MEDICALE. 2016;45(6 Pt 2):e179-e192

New therapeutic approaches in rheumatoid arthritis.

van Vollenhoven RF
Article: RHEUMATOLOGY. 2016;55(4):729-734

Does disease activity at start of biologic therapy influence work-loss in RA patients?

Olofsson T; Johansson K; Eriksson JK; van Vollenhoven R; Miller H; Petersson IF; Askling J; Neovius M
Article: ARTHRITIS CARE & RESEARCH. 2016;68(4):562-569

Choosing Wisely in Daily Practice: An Intervention Study on Antinuclear Antibody Testing by Rheumatologists.

Lesuis N; Hulscher MEJL; Piek E; Demirel H; van der Laan-Baalbergen N; Meek I; van Vollenhoven RF; den Broeder AA
Article: ARTHRITIS RESEARCH & THERAPY. 2016;18:50

Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.

Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Ancuta I; Pavelka K; Nordström DC; Gabay C; Canhão H; Tomsic M; van Riel PLCM; Gomez-Reino J; Kvien TK; van Vollenhoven RF; Rheumatic Diseases Portuguese Register
Article: RHEUMATOLOGY. 2016;55(2):252-262

The frequency and outcome of lupus nephritis: results from an international inception cohort study.

Hanly JG; O'Keeffe AG; Su L; Urowitz MB; Romero-Diaz J; Gordon C; Bae S-C; Bernatsky S; Clarke AE; Wallace DJ; Merrill JT; Isenberg DA; Rahman A; Ginzler EM; Fortin P; Gladman DD; Sanchez-Guerrero J; Petri M; Bruce IN; Dooley MA; Ramsey-Goldman R; Aranow C; Alarcón GS; Fessler BJ; Steinsson K; Nived O; Sturfelt GK; Manzi S; Khamashta MA; van Vollenhoven RF; Zoma AA; Ramos-Casals M; Ruiz-Irastorza G; Lim SS; Stoll T; Inanc M; Kalunian KC; Kamen DL; Maddison P; Peschken CA; Jacobsen S; Askanase A; Theriault C; Thompson K; Farewell V
Article: RHEUMATOLOGY. 2016;55(2):230-236

Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.

Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge E-M; Pavelka K; Nordström DC; Canhão H; Tomšič M; van Vollenhoven R; Gabay C
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(2):332-340

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Merrill JT; van Vollenhoven RF; Buyon JP; Furie RA; Stohl W; Morgan-Cox M; Dickson C; Anderson PW; Lee C; Berclaz P-Y; Dörner T
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(2):356-361

Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.

Kastbom A; Forslind K; Ernestam S; Geborek P; Karlsson JA; Petersson IF; Saevarsdottir S; Klareskog L; van Vollenhoven RF; Lundberg K
Article: LUPUS SCIENCE & MEDICINE. 2016;3(1):e000135

The association between diet and glucocorticoid treatment in patients with SLE.

Lourdudoss C; Hafström I; Frostegård J; van Vollenhoven R
Article: RMD OPEN. 2016;2(1):e000133

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.

Chatzidionysiou K; Turesson C; Teleman A; Knight A; Lindqvist E; Larsson P; Cöster L; Forslind K; van Vollenhoven R; Heimbürger M
Article: ARTHRITIS & RHEUMATOLOGY. 2016;68(1):46-55

VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis.

Genovese MC; van Vollenhoven RF; Pacheco-Tena C; Zhang Y; Kinnman N
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(1):52-58

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.

van Vollenhoven RF; Østergaard M; Leirisalo-Repo M; Uhlig T; Jansson M; Larsson E; Brock F; Franck-Larsson K
Article: PLOS ONE. 2016;11(6):e0157961

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.

Quattrocchi E; Østergaard M; Taylor PC; van Vollenhoven RF; Chu M; Mallett S; Perry H; Kurrasch R
Article: RMD OPEN. 2016;2(1):e000213

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.

Rubbert-Roth A; Sebba A; Brockwell L; Kelman A; Porter-Brown B; Pulley J; Napalkov P; van Vollenhoven RF
Article: RMD OPEN. 2016;2(1):e000195

Practice what you preach? An exploratory multilevel study on rheumatoid arthritis guideline adherence by rheumatologists.

Lesuis N; den Broeder AA; Hulscher MEJL; van Vollenhoven RF
Article: LUPUS SCIENCE & MEDICINE. 2016;3(1):e000143

Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort.

Urowitz MB; Gladman DD; Anderson NM; Su J; Romero-Diaz J; Bae SC; Fortin PR; Sanchez-Guerrero J; Clarke A; Bernatsky S; Gordon C; Hanly JG; Wallace DJ; Isenberg D; Rahman A; Merrill J; Ginzler E; Alarcón GS; Fessler BF; Petri M; Bruce IN; Khamashta M; Aranow C; Dooley M; Manzi S; Ramsey-Goldman R; Sturfelt G; Nived O; Steinsson K; Zoma A; Ruiz-Irastorza G; Lim S; Kalunian KC; Ỉnanç M; van Vollenhoven R; Ramos-Casals M; Kamen DL; Jacobsen S; Peschken C; Askanase A; Stoll T
Article: RMD OPEN. 2016;2(1):e000197

Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial.

Hambardzumyan K; Bolce RJ; Saevarsdottir S; Forslind K; Wallman JK; Cruickshank SE; Sasso EH; Chernoff D; van Vollenhoven RF
Article: RMD OPEN. 2016;2(2):e000323

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials.

Emamikia S; Arkema EV; Györi N; Detert J; Chatzidionysiou K; Dougados M; Burmester GR; van Vollenhoven R
Article: LUPUS SCIENCE & MEDICINE. 2016;3(1):e000163

Off-label use of rituximab for systemic lupus erythematosus in Europe.

Rydén-Aulin M; Boumpas D; Bultink I; Callejas Rubio JL; Caminal-Montero L; Castro A; Colodro Ruiz A; Doria A; Dörner T; Gonzalez-Echavarri C; Gremese E; Houssiau FA; Huizinga T; Inanç M; Isenberg D; Iuliano A; Jacobsen S; Jimenéz-Alonso J; Kovács L; Mariette X; Mosca M; Nived O; Oristrell J; Ramos-Casals M; Rascón J; Ruiz-Irastorza G; Sáez-Comet L; Salvador Cervelló G; Sebastiani GD; Squatrito D; Szücs G; Voskuyl A; van Vollenhoven R
Article: JOURNAL OF RHEUMATOLOGY. 2015;42(12):2288-2295

Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.

Hui-Yuen JS; Reddy A; Taylor J; Li X; Eichenfield AH; Bermudez LM; Starr AJ; Imundo LF; Buyon J; Furie RA; Kamen DL; Manzi S; Petri M; Ramsey-Goldman R; van Vollenhoven RF; Wallace DJ; Askanase A
Article: ARTHRITIS RESEARCH & THERAPY. 2015;17:325

Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.

Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TWJ; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2015;44(6):431-437

Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.

Chatzidionysiou K; Kristensen L-E; Eriksson J; Askling J; van Vollenhoven R; ARTIS Group
Article: ARTHRITIS & RHEUMATOLOGY. 2015;67(11):2855-2860

Brief report: enhancement of patient recruitment in rheumatoid arthritis clinical trials using a multi-biomarker disease activity score as an inclusion criterion.

van Vollenhoven RF; Bolce R; Hambardzumyan K; Saevarsdottir S; Forslind K; Petersson IF; Sasso EH; Hwang CC; Segurado OG; Geborek P
Article: ARTHRITIS & RHEUMATOLOGY. 2015;67(11):2828-2836

Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial.

van Vollenhoven RF; Wax S; Li Y; Tak PP
Article: JOURNAL OF RHEUMATOLOGY. 2015;42(10):1761-1766

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years.

van Vollenhoven RF; Fleischmann RM; Furst DE; Lacey S; Lehane PB
Article: BMC MEDICINE. 2015;13:247

Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial.

Levitsky A; Erlandsson MC; van Vollenhoven RF; Bokarewa MI
Article: ARTHRITIS RESEARCH & THERAPY. 2015;17(1):245

Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.

Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2015;44(5):348-353

Predicted vs. observed radiographic progression in early rheumatoid arthritis (POPeRA): results from a randomized trial.

Levitsky A; Forslind K; van Vollenhoven RF; SWEFOT trial group
Article: ARTHRITIS CARE & RESEARCH. 2015;67(9):1237-1245

Treatment Algorithms in Systemic Lupus Erythematosus.

Muangchan C; van Vollenhoven RF; Bernatsky SR; Smith CD; Hudson M; Inanç M; Rothfield NF; Nash PT; Furie RA; Senécal J-L; Chandran V; Burgos-Vargas R; Ramsey-Goldman R; Pope JE
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(9):1706-1713

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.

Bruce IN; O'Keeffe AG; Farewell V; Hanly JG; Manzi S; Su L; Gladman DD; Bae S-C; Sanchez-Guerrero J; Romero-Diaz J; Gordon C; Wallace DJ; Clarke AE; Bernatsky S; Ginzler EM; Isenberg DA; Rahman A; Merrill JT; Alarcón GS; Fessler BJ; Fortin PR; Petri M; Steinsson K; Dooley MA; Khamashta MA; Ramsey-Goldman R; Zoma AA; Sturfelt GK; Nived O; Aranow C; Mackay M; Ramos-Casals M; van Vollenhoven RF; Kalunian KC; Ruiz-Irastorza G; Lim S; Kamen DL; Peschken CA; Inanc M; Urowitz MB
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(8):1567-1570

Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study.

Smolen JS; Weinblatt ME; van der Heijde D; Rigby WFC; van Vollenhoven R; Bingham CO; Veenhuizen M; Gill A; Zhao F; Komocsar WJ; Berclaz P-Y; Ortmann R; Lee C
Article: RHEUMATOLOGY. 2015;54(8):1472-1477

Does disease activity at the start of biologic therapy influence health care costs in patients with RA?

Johansson K; Eriksson JK; van Vollenhoven R; Miller H; Askling J; Neovius M; ARTIS Study Group
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(8):1509-1514

Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.

Saevarsdottir S; Rezaei H; Geborek P; Petersson I; Ernestam S; Albertsson K; Forslind K; van Vollenhoven RF; SWEFOT study group
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(8):1530-1536

Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.

Parker B; Urowitz MB; Gladman DD; Lunt M; Donn R; Bae S-C; Sanchez-Guerrero J; Romero-Diaz J; Gordon C; Wallace DJ; Clarke AE; Bernatsky S; Ginzler EM; Isenberg DA; Rahman A; Merrill JT; Alarcón GS; Fessler BJ; Fortin PR; Hanly JG; Petri M; Steinsson K; Dooley MA; Manzi S; Khamashta MA; Ramsey-Goldman R; Zoma AA; Sturfelt GK; Nived O; Aranow C; Mackay M; Ramos-Casals M; van Vollenhoven RF; Kalunian KC; Ruiz-Irastorza G; Lim SS; Kamen DL; Peschken CA; Inanc M; Bruce IN
Article: ARTHRITIS & RHEUMATOLOGY. 2015;67(7):1837-1847

Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Hanly JG; Su L; Urowitz MB; Romero-Diaz J; Gordon C; Bae S-C; Bernatsky S; Clarke AE; Wallace DJ; Merrill JT; Isenberg DA; Rahman A; Ginzler EM; Petri M; Bruce IN; Dooley MA; Fortin P; Gladman DD; Sanchez-Guerrero J; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Alarcón GS; Fessler BJ; Manzi S; Nived O; Sturfelt GK; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Theriault C; Thompson K; Farewell V
Article: RMD OPEN. 2015;1(1):e000106

Detection of clinically manifest and silent synovitis in the hands and wrists by fluorescence optical imaging.

Kisten Y; Györi N; Af Klint E; Rezaei H; Levitsky A; Karlsson A; van Vollenhoven R
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(6):1102-1109

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.

Hambardzumyan K; Bolce R; Saevarsdottir S; Cruickshank SE; Sasso EH; Chernoff D; Forslind K; Petersson IF; Geborek P; van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(6):1094-1101

Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.

Eriksson JK; Karlsson JA; Bratt J; Petersson IF; van Vollenhoven RF; Ernestam S; Geborek P; Neovius M
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(5):890-896

Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.

Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R; ARTIS group
Article: RMD OPEN. 2015;1(1):e000044

The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region.

Mariette X; Vencovsky J; Lortholary O; Gomez-Reino J; de Longueville M; Ralston P; Weinblatt M; van Vollenhoven R
Article: BMJ-BRITISH MEDICAL JOURNAL. 2015;350:h1389

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.

van Herwaarden N; van der Maas A; Minten MJM; van den Hoogen FHJ; Kievit W; van Vollenhoven RF; Bijlsma JWJ; van den Bemt BJF; den Broeder AA
Article: LUPUS. 2015;24(1):42-49

Anti-C1q antibodies in systemic lupus erythematosus.

Orbai A-M; Truedsson L; Sturfelt G; Nived O; Fang H; Alarcón GS; Gordon C; Merrill J; Fortin PR; Bruce IN; Isenberg DA; Wallace DJ; Ramsey-Goldman R; Bae S-C; Hanly JG; Sanchez-Guerrero J; Clarke AE; Aranow CB; Manzi S; Urowitz MB; Gladman DD; Kalunian KC; Costner MI; Werth VP; Zoma A; Bernatsky S; Ruiz-Irastorza G; Khamashta MA; Jacobsen S; Buyon JP; Maddison P; Dooley MA; Van Vollenhoven RF; Ginzler E; Stoll T; Peschken C; Jorizzo JL; Callen JP; Lim SS; Fessler BJ; Inanc M; Kamen DL; Rahman A; Steinsson K; Franks AG; Sigler L; Hameed S; Pham N; Brey R; Weisman MH; McGwin G; Magder LS; Petri M
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(1):96-103

Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.

Bykerk VP; Cush J; Winthrop K; Calabrese L; Lortholary O; de Longueville M; van Vollenhoven R; Mariette X
Article: ANNALS OF THE RHEUMATIC DISEASES. 2014;73(12):2094-2100

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.

Keystone E; Landewé R; van Vollenhoven R; Combe B; Strand V; Mease P; Shaughnessy L; VanLunen B; van der Heijde D
Article: ARTHRITIS RESEARCH & THERAPY. 2014;16(5):448

Diagnostic utility of musculoskeletal ultrasound in patients with suspected arthritis--a probabilistic approach.

Rezaei H; Torp-Pedersen S; af Klint E; Backheden M; Kisten Y; Györi N; van Vollenhoven RF
Article: ARTHRITIS CARE & RESEARCH. 2014;66(8):1167-1176

25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort.

Lertratanakul A; Wu P; Dyer A; Urowitz M; Gladman D; Fortin P; Bae S-C; Gordon C; Clarke A; Bernatsky S; Hanly JG; Isenberg D; Rahman A; Merrill J; Wallace DJ; Ginzler E; Khamashta M; Bruce I; Nived O; Sturfelt G; Steinsson K; Manzi S; Dooley MA; Kalunian K; Petri M; Aranow C; Font J; van Vollenhoven R; Stoll T; Ramsey-Goldman R
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2014;370(25):2377-2386

Tofacitinib versus methotrexate in rheumatoid arthritis.

Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF; ORAL Start Investigators
Article: JOURNAL OF RHEUMATOLOGY. 2014;41(5):875-880

American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort.

Urowitz MB; Gladman DD; Ibañez D; Sanchez-Guerrero J; Romero-Diaz J; Gordon C; Bae S-C; Clarke AE; Bernatsky S; Fortin PR; Hanly JG; Isenberg D; Rahman A; Wallace DJ; Ginzler E; Petri M; Bruce IN; Merrill JT; Nived O; Sturfelt G; Dooley MA; Alarcón GS; Fessler B; Steinsson K; Ramsey-Goldman R; Zoma A; Khamashta M; Manzi S; van Vollenhoven R; Ramos-Casals M; Aranow C; Stoll T
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2014;32(3):315-323

The early clinical course of infliximab treatment in rheumatoid arthritis: results from the REMARK observational study.

Westhovens R; van Vollenhoven RF; Boumpas DT; Brzosko M; Svensson K; Bjorneboe O; Meeuwisse CM; Srinivasan S; Gaudin P; Smolen JS; Rahman MU; Nelissen RL; Vastesaeger N
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2014;32(3):390-394

Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity.

van Herwaarden N; Herfkens-Hol S; van der Maas A; van den Bemt BJF; van Vollenhoven RF; Bijlsma JWJ; den Broeder AA
Article: TRAVEL MEDICINE AND INFECTIOUS DISEASE. 2014;12(2):134-142

Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study.

Askling HH; Rombo L; van Vollenhoven R; Hallén I; Thörner Å; Nordin M; Herzog C; Kantele A
Article: LUPUS. 2014;23(3):299-304

Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center.

Lourdudoss C; Vollenhoven RV
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2014;79(2):149-155

Peripheral and site-specific CD4(+) CD28(null) T cells from rheumatoid arthritis patients show distinct characteristics.

Pieper J; Johansson S; Snir O; Linton L; Rieck M; Buckner JH; Winqvist O; van Vollenhoven R; Malmström V
Article: LANCET. 2014;383(9914):321-332

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.

Smolen JS; Emery P; Fleischmann R; van Vollenhoven RF; Pavelka K; Durez P; Guérette B; Kupper H; Redden L; Arora V; Kavanaugh A
Article: CURRENT RHEUMATOLOGY REPORTS. 2014;16(9):444

Rituximab and lupus--a promising pair?

Ekö SL; van Vollenhoven RF
Article: LUPUS SCIENCE & MEDICINE. 2014;1(1):e000028

Editorial.

Buyon J; van Vollenhoven R
Article: LUPUS SCIENCE & MEDICINE. 2014;1(1):e000033

Lupus Science and Medicine: the Editors present highlights for the bedside and for the bench in the inaugural issue.

Buyon J; van Vollenhoven R
Article: ANNALS OF THE RHEUMATIC DISEASES. 2013;72(12):1927-1933

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.

Karlsson JA; Neovius M; Nilsson J-Å; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2013;14(6):863-873

The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice.

Lekander I; Borgström F; Lysholm J; van Vollenhoven RF; Lindblad S; Geborek P; Kobelt G
Article: ARTHRITIS & RHEUMATOLOGY. 2013;65(11):2887-2897

Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study.

Hanly JG; Urowitz MB; O'Keeffe AG; Gordon C; Bae S-C; Sanchez-Guerrero J; Romero-Diaz J; Clarke AE; Bernatsky S; Wallace DJ; Ginzler EM; Isenberg DA; Rahman A; Merrill JT; Petri M; Fortin PR; Gladman DD; Fessler BJ; Alarcón GS; Bruce IN; Dooley MA; Steinsson K; Khamashta MA; Ramsey-Goldman R; Manzi S; Sturfelt GK; Nived O; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Aranow C; Mackay M; Ruiz-Irastorza G; Kalunian KC; Lim SS; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Theriault C; Thompson K; Farewell V
Article: BMC MUSCULOSKELETAL DISORDERS. 2013;14:299

Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study.

den Broeder AA; van Herwaarden N; van der Maas A; van den Hoogen FHJ; Bijlsma JW; van Vollenhoven RF; van den Bemt BJF
Article: ARTHRITIS & RHEUMATOLOGY. 2013;65(10):2661-2671

Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.

Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
Article: LUPUS. 2013;22(11):1118-1127

Health-related quality of life, fatigue and mood in patients with SLE and high levels of pain compared to controls and patients with low levels of pain.

Waldheim E; Elkan A-C; Pettersson S; van Vollenhoven R; Bergman S; Frostegård J; Welin Henriksson E
Article: ANNALS OF THE RHEUMATIC DISEASES. 2013;72(9):1496-1502

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.

van Vollenhoven RF; Emery P; Bingham CO; Keystone EC; Fleischmann RM; Furst DE; Tyson N; Collinson N; Lehane PB
Article: JAMA INTERNAL MEDICINE. 2013;173(15):1407-1414

Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial.

Eriksson JK; Neovius M; Bratt J; Petersson IF; van Vollenhoven RF; Geborek P; Ernestam S
Article: BMC IMMUNOLOGY. 2013;14:34

CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients.

Pieper J; Herrath J; Raghavan S; Muhammad K; Vollenhoven RV; Malmström V
Article: ANNALS OF THE RHEUMATIC DISEASES. 2013;72(8):1308-1314

Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.

Parker B; Urowitz MB; Gladman DD; Lunt M; Bae S-C; Sanchez-Guerrero J; Romero-Diaz J; Gordon C; Wallace DJ; Clarke AE; Bernatsky S; Ginzler EM; Isenberg DA; Rahman A; Merrill JT; Alarcón GS; Fessler BJ; Fortin PR; Hanly JG; Petri M; Steinsson K; Dooley M-A; Manzi S; Khamashta MA; Ramsey-Goldman R; Zoma AA; Sturfelt GK; Nived O; Aranow C; Mackay M; Ramos-Casals M; van Vollenhoven RF; Kalunian KC; Ruiz-Irastorza G; Lim S; Kamen DL; Peschken CA; Inanc M; Bruce IN
Article: ARTHRITIS & RHEUMATOLOGY. 2013;65(8):2143-2153

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.

Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW; BLISS-52 and BLISS-76 Study Groups
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2013;31(4 Suppl 78):S82-S85

New drugs in systemic lupus erythematosus: when to start and when to stop.

Mosca M; van Vollenhoven R
Article: ANNALS OF THE RHEUMATIC DISEASES. 2013;72(7):1156-1162

Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate.

Smolen JS; van der Heijde DM; Keystone EC; van Vollenhoven RF; Goldring MB; Guérette B; Cifaldi MA; Chen N; Liu S; Landewé RBM
Article: LUPUS. 2013;22(8):793-801

Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports.

Bexelius C; Wachtmeister K; Skare P; Jönsson L; Vollenhoven RV
Article: LUPUS. 2013;22(8):819-826

Limitations of current treatments for systemic lupus erythematosus: a patient and physician survey.

Strand V; Galateanu C; Pushparajah DS; Nikaï E; Sayers J; Wood R; van Vollenhoven RF
Article: BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY. 2013;27(3):341-349

Biologics in SLE: towards new approaches.

van Vollenhoven RF; Parodis I; Levitsky A
Article: JOURNAL OF RHEUMATOLOGY. 2013;40(6):768-780

Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.

Genovese MC; Rubbert-Roth A; Smolen JS; Kremer J; Khraishi M; Gómez-Reino J; Sebba A; Pilson R; Williams S; Van Vollenhoven R
Article: LANCET. 2013;381(9877):1541-1550

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.

Gabay C; Emery P; van Vollenhoven R; Dikranian A; Alten R; Pavelka K; Klearman M; Musselman D; Agarwal S; Green J; Kavanaugh A; ADACTA Study Investigators
Article: RHEUMATOLOGY. 2013;52(5):847-855

Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response.

Jónsdóttir T; Zickert A; Sundelin B; Henriksson EW; van Vollenhoven RF; Gunnarsson I
Article: BMC MUSCULOSKELETAL DISORDERS. 2013;14:79

Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial.

Rezaei H; Saevarsdottir S; Geborek P; Petersson IF; van Vollenhoven RF; Forslind K
Article: VALUE IN HEALTH. 2013;16(2):251-258

The comparison of trial data-based and registry data-based cost-effectiveness of infliximab treatment for rheumatoid arthritis in Sweden using a modeling approach.

Lekander I; Kobelt G; Svarvar P; Ljung T; van Vollenhoven R; Borgström F
Article: LUPUS. 2013;22(2):144-154

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.

Wallace DJ; Navarra S; Petri MA; Gallacher A; Thomas M; Furie R; Levy RA; van Vollenhoven RF; Cooper S; Zhong ZJ; Freimuth W; Cervera R; BLISS-52 and -76, and LBSL02 Study Groups
Article: LUPUS. 2013;22(2):136-143

Extent and characteristics of self-reported pain in patients with systemic lupus erythematosus.

Waldheim E; Elkan A-C; Bergman S; Frostegård J; van Vollenhoven R; Henriksson EW
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2013;42(3):190-195

Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort.

Chatzidionysiou K; van Vollenhoven RF
Article: RHEUMATOLOGY. 2012;51(12):2204-2214

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.

Weinblatt ME; Fleischmann R; Huizinga TWJ; Emery P; Pope J; Massarotti EM; van Vollenhoven RF; Wollenhaupt J; Bingham CO; Duncan B; Goel N; Davies OR; Dougados M
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(11):1865-1867

Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study.

Arkema EV; van Vollenhoven RF; Askling J; ARTIS Study Group
Article: JOURNAL OF RHEUMATOLOGY. 2012;39(10):2008-2011

Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study.

Nordström D; Knight A; Luukkainen R; van Vollenhoven R; Rantalaiho V; Kajalainen A; Brun JG; Proven A; Ljung L; Kautiainen H; Pettersson T
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(9):1502-1509

Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study.

Hanly JG; Urowitz MB; Su L; Gordon C; Bae S-C; Sanchez-Guerrero J; Romero-Diaz J; Wallace DJ; Clarke AE; Ginzler E; Merrill JT; Isenberg DA; Rahman A; Petri M; Fortin PR; Gladman D; Bruce IN; Steinsson K; Dooley M; Khamashta MA; Alarcón GS; Fessler BJ; Ramsey-Goldman R; Manzi S; Zoma AA; Sturfelt GK; Nived O; Aranow C; Mackay M; Ramos-Casals M; van Vollenhoven R; Kalunian KC; Ruiz-Irastorza G; Lim S; Kamen DL; Peschken CA; Inanc M; Theriault C; Thompson K; Farewell V
Article: RHEUMATOLOGY. 2012;51(9):1628-1638

Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial.

Keystone EC; Combe B; Smolen J; Strand V; Goel N; van Vollenhoven R; Mease P; Landewé R; Fleischmann R; Luijtens K; van der Heijde D
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2012;367(6):508-519

Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

van Vollenhoven RF; Fleischmann R; Cohen S; Lee EB; García Meijide JA; Wagner S; Forejtova S; Zwillich SH; Gruben D; Koncz T; Wallenstein GV; Krishnaswami S; Bradley JD; Wilkinson B; ORAL Standard Investigators
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(8):1343-1349

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

van Vollenhoven RF; Petri MA; Cervera R; Roth DA; Ji BN; Kleoudis CS; Zhong ZJ; Freimuth W
Article: ARTHRITIS & RHEUMATOLOGY. 2012;64(8):2677-2686

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

Petri M; Orbai A-M; Alarcón GS; Gordon C; Merrill JT; Fortin PR; Bruce IN; Isenberg D; Wallace DJ; Nived O; Sturfelt G; Ramsey-Goldman R; Bae S-C; Hanly JG; Sánchez-Guerrero J; Clarke A; Aranow C; Manzi S; Urowitz M; Gladman D; Kalunian K; Costner M; Werth VP; Zoma A; Bernatsky S; Ruiz-Irastorza G; Khamashta MA; Jacobsen S; Buyon JP; Maddison P; Dooley MA; van Vollenhoven RF; Ginzler E; Stoll T; Peschken C; Jorizzo JL; Callen JP; Lim SS; Fessler BJ; Inanc M; Kamen DL; Rahman A; Steinsson K; Franks AG; Sigler L; Hameed S; Fang H; Pham N; Brey R; Weisman MH; McGwin G; Magder LS
Article: BMC MEDICINE. 2012;10:82

Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study.

Lesuis N; Befrits R; Nyberg F; van Vollenhoven RF
Article: CYTOKINE. 2012;59(2):392-399

Pregnancy-associated inflammatory markers are elevated in pregnant women with systemic lupus erythematosus.

Björkander S; Bremme K; Persson J-O; van Vollenhoven RF; Sverremark-Ekström E; Holmlund U
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(7):1203-1206

Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study.

Arkema EV; Neovius M; Joelsson JK; Simard JF; van Vollenhoven RF
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2012;30(4 Suppl 73):S112-S115

Treat-to-target in systemic lupus erythematosus: where are we today?

Mosca M; Boumpas DT; Bruce IN; Cervera R; Czirjak L; Dörner T; Houssiau F; Jacobsen S; Schneider M; Smolen JS; Voskuyl AE; van Vollenhoven RF
Article: LANCET. 2012;379(9827):1712-1720

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.

van Vollenhoven RF; Geborek P; Forslind K; Albertsson K; Ernestam S; Petersson IF; Chatzidionysiou K; Bratt J; Swefot study group
Article: ARTHRITIS & RHEUMATOLOGY. 2012;64(5):1579-1588

Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.

Bengtsson AA; Sturfelt G; Lood C; Rönnblom L; van Vollenhoven RF; Axelsson B; Sparre B; Tuvesson H; Ohman MW; Leanderson T
Article: ARTHRITIS RESEARCH & THERAPY. 2012;14(3):R100

Anti-type II collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis.

Mullazehi M; Wick MC; Klareskog L; van Vollenhoven R; Rönnelid J
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(3):351-357

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.

Tak PP; Rigby W; Rubbert-Roth A; Peterfy C; van Vollenhoven RF; Stohl W; Healy E; Hessey E; Reynard M; Shaw T
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(3):374-377

Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration.

Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; van Riel PLCM; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF; Gabay C
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(2):186-191

In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial.

Rezaei H; Saevarsdottir S; Forslind K; Albertsson K; Wallin H; Bratt J; Ernestam S; Geborek P; Pettersson IF; van Vollenhoven RF
Article: PHARMACOGENETICS AND GENOMICS. 2012;22(1):1-9

Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis.

Dervieux T; Wessels JAM; Kremer JM; Padyukov L; Seddighzadeh M; Saevarsdottir S; van Vollenhoven RF; Klareskog L; Huizinga TW; Guchelaar H-J
Article: ARTHRITIS CARE & RESEARCH. 2012;64(1):132-137

Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort.

Urowitz MB; Gladman DD; Ibañez D; Fortin PR; Bae SC; Gordon C; Clarke A; Bernatsky S; Hanly JG; Isenberg D; Rahman A; Sanchez-Guerrero J; Wallace DJ; Ginzler E; Alarcón GS; Merrill JT; Bruce IN; Sturfelt G; Nived O; Steinsson K; Khamashta M; Petri M; Manzi S; Ramsey-Goldman R; Dooley MA; van Vollenhoven RF; Ramos M; Stoll T; Zoma A; Kalunian K; Aranow C
Article: BMJ OPEN. 2012;2(5):e001524

Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study.

Kastbom A; Cöster L; Arlestig L; Chatzidionysiou A; van Vollenhoven RF; Padyukov L; Rantapää-Dahlqvist S; Saevarsdottir S
Article: ARTHRITIS & RHEUMATOLOGY. 2011;63(12):3918-3930

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF; BLISS-76 Study Group
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(11):1895-1904

Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis.

Mariette X; Matucci-Cerinic M; Pavelka K; Taylor P; van Vollenhoven R; Heatley R; Walsh C; Lawson R; Reynolds A; Emery P
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(10):1726-1732

Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.

Hanly JG; Urowitz MB; Su L; Bae S-C; Gordon C; Clarke A; Bernatsky S; Vasudevan A; Isenberg D; Rahman A; Wallace DJ; Fortin PR; Gladman D; Romero-Diaz J; Sanchez-Guerrero J; Dooley MA; Bruce I; Steinsson K; Khamashta M; Manzi S; Ramsey-Goldman R; Sturfelt G; Nived O; van Vollenhoven R; Ramos-Casals M; Aranow C; Mackay M; Kalunian K; Alarcón GS; Fessler BJ; Ruiz-Irastorza G; Petri M; Lim S; Kamen D; Peschken C; Farewell V; Thompson K; Theriault C; Merrill JT
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(9):1575-1580

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.

Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PLCM; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Article: ARTHRITIS & RHEUMATOLOGY. 2011;63(7):1782-1792

Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial.

van Vollenhoven RF; Kinnman N; Vincent E; Wax S; Bathon J
Article: ARTHRITIS CARE & RESEARCH. 2011;63(7):1068-1072

Decreased live births in women with systemic lupus erythematosus.

Vinet E; Clarke AE; Gordon C; Urowitz MB; Hanly JG; Pineau CA; Isenberg D; Rahman A; Wallace D; Alarcón GS; Bruce I; Petri M; Dooley MA; Kalunian K; Maddison P; Aranow C; van Vollenhoven R; Bernatsky S
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(6):996-1002

Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial.

Strand V; Smolen JS; van Vollenhoven RF; Mease P; Burmester GR; Hiepe F; Khanna D; Nikaï E; Coteur G; Schiff M
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(6):1095-1098

Antibodies to citrullinated α-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis.

Fisher BA; Plant D; Brode M; van Vollenhoven RF; Mathsson L; Symmons D; Lundberg K; Rönnelid J; Venables PJ
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(6):961-967

SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus.

Hanly JG; Urowitz MB; Jackson D; Bae SC; Gordon C; Wallace DJ; Clarke A; Bernatsky S; Vasudevan A; Isenberg D; Rahman A; Sanchez-Guerrero J; Romero-Diaz J; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Steinsson K; Khamashta M; Alarcón GS; Fessler B; Petri M; Manzi S; Nived O; Sturfelt G; Ramsey-Goldman R; Dooley MA; Aranow C; Van Vollenhoven R; Ramos-Casals M; Zoma A; Kalunian K; Farewell V; Systemic Lupus International Collaborating Clinics
Article: ISRN RHEUMATOLOGY. 2011;2011:463124-5

Patient preference assessment reveals disease aspects not covered by recommended outcomes in polymyositis and dermatomyositis.

Alemo Munters L; van Vollenhoven RF; Alexanderson H
Article: LUPUS. 2011;20(3):250-255

Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity.

Ippolito A; Wallace DJ; Gladman D; Fortin PR; Urowitz M; Werth V; Costner M; Gordon C; Alarcón GS; Ramsey-Goldman R; Maddison P; Clarke A; Bernatsky S; Manzi S; Bae S-C; Merrill JT; Ginzler E; Hanly JG; Nived O; Sturfelt G; Sanchez-Guerrero J; Bruce I; Aranow C; Isenberg D; Zoma A; Magder LS; Buyon J; Kalunian K; Dooley MA; Steinsson K; van Vollenhoven RF; Stoll T; Weisman M; Petri M
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(3):469-475

Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.

Saevarsdottir S; Wallin H; Seddighzadeh M; Ernestam S; Geborek P; Petersson IF; Bratt J; van Vollenhoven RF; SWEFOT Trial Investigators Group
Article: ARTHRITIS RESEARCH & THERAPY. 2011;13(5):R141

Integrated safety in tocilizumab clinical trials.

Schiff MH; Kremer JM; Jahreis A; Vernon E; Isaacs JD; van Vollenhoven RF
Article: RHEUMATOLOGY. 2011;50(1):204-213

Ten years with biologics: to whom do data on effectiveness and safety apply?

Simard JF; Arkema EV; Sundström A; Geborek P; Saxne T; Baecklund E; Coster L; Dackhammar C; Jacobsson L; Feltelius N; Lindblad S; Rantapää-Dahlqvist S; Klareskog L; van Vollenhoven RF; Neovius M; Askling J
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(1):39-46

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.

Tak PP; Rigby WF; Rubbert-Roth A; Peterfy CG; van Vollenhoven RF; Stohl W; Hessey E; Chen A; Tyrrell H; Shaw TM; IMAGE Investigators
Article: ARTHRITIS CARE & RESEARCH. 2011;63(1):128-134

American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial.

van Vollenhoven RF; Felson D; Strand V; Weinblatt ME; Luijtens K; Keystone EC
Article: RHEUMATOLOGY. 2010;49(11):2098-2103

Patient-reported 28 swollen and tender joint counts accurately represent RA disease activity and can be used to assess therapy responses at the group level.

Riazzoli J; Nilsson J-Å; Teleman A; Petersson IF; Rantapää-Dahlqvist S; Jacobsson LTH; van Vollenhoven RF
Article: RHEUMATOLOGY. 2010;49(8):1502-1504

Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts.

Jónsdóttir T; Gunnarsson I; Mourão AF; Lu TY; van Vollenhoven RF; Isenberg D
Article: LUPUS. 2010;19(8):949-956

Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus.

Nossent J; Kiss E; Rozman B; Pokorny G; Vlachoyiannopoulos P; Olesinska M; Marchesoni A; Mosca M; Påi S; Manger K; Schneider M; Nielsen H; van Vollenhoven R; Swaak T
Article: ARTHRITIS CARE & RESEARCH. 2010;62(6):881-887

Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus.

Urowitz MB; Gladman D; Ibañez D; Bae SC; Sanchez-Guerrero J; Gordon C; Clarke A; Bernatsky S; Fortin PR; Hanly JG; Wallace DJ; Isenberg D; Rahman A; Alarcón GS; Merrill JT; Ginzler E; Khamashta M; Nived O; Sturfelt G; Bruce IN; Steinsson K; Manzi S; Ramsey-Goldman R; Dooley MA; Zoma A; Kalunian K; Ramos M; Van Vollenhoven RF; Aranow C; Stoll T; Petri M; Maddison P; Systemic Lupus International Collaborating Clinics
Article: DISCOVERY MEDICINE. 2010;9(47):319-327

New and future agents in the treatment of rheumatoid arthritis.

van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2010;69(3):529-535

Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus.

Hanly JG; Urowitz MB; Su L; Bae SC; Gordon C; Wallace DJ; Clarke A; Bernatsky S; Isenberg D; Rahman A; Alarcón GS; Gladman DD; Fortin PR; Sanchez-Guerrero J; Romero-Diaz J; Merrill JT; Ginzler E; Bruce IN; Steinsson K; Khamashta M; Petri M; Manzi S; Dooley MA; Ramsey-Goldman R; Van Vollenhoven R; Nived O; Sturfelt G; Aranow C; Kalunian K; Ramos-Casals M; Zoma A; Douglas J; Thompson K; Farewell V; Systemic Lupus International Collaborating Clinics
Article: JOURNAL OF RHEUMATOLOGY. 2010;37(3):558-567

Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials.

van Vollenhoven RF; Emery P; Bingham CO; Keystone EC; Fleischmann R; Furst DE; Macey K; Sweetser M; Kelman A; Rao R
Article: ANNALS OF THE RHEUMATIC DISEASES. 2010;69(2):394-399

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.

Van den Bosch F; Manger B; Goupille P; McHugh N; Rødevand E; Holck P; van Vollenhoven RF; Leirisalo-Repo M; Fitzgerald O; Kron M; Frank M; Kary S; Kupper H
Article: ARTHRITIS CARE & RESEARCH. 2010;62(2):226-234

Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study.

van Vollenhoven RF; Cifaldi MA; Ray S; Chen N; Weisman MH
Article: ARTHRITIS & RHEUMATOLOGY. 2010;62(2):351-358

The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine.

van Vollenhoven RF; Houbiers JGA; Buttgereit F; In 't Hout J; Boers M; Leij S; Kvien TK; Dijkmans BAC; Szczepański L; Szombati I; Sierakowski S; Miltenburg AMM
Article: ANNALS OF THE RHEUMATIC DISEASES. 2010;69(1):126-131

Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry).

Augustsson J; Neovius M; Cullinane-Carli C; Eksborg S; van Vollenhoven RF
Article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2010;26(1):54-61

Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden.

Lekander I; Borgström F; Svarvar P; Ljung T; Carli C; van Vollenhoven RF
Article: ARTHRITIS & RHEUMATOLOGY. 2009;61(11):1592-1600

Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis.

Kavanaugh A; Smolen JS; Emery P; Purcaru O; Keystone E; Richard L; Strand V; van Vollenhoven RF
Article: ARTHRITIS & RHEUMATOLOGY. 2009;60(11):3180-3189

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Article: LANCET. 2009;374(9688):459-466

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.

van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Cöster L; Waltbrand E; Zickert A; Theander J; Thörner A; Hellström H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wörnert M; Bratt J
Article: JOURNAL OF RHEUMATOLOGY. 2009;36(7):1429-1441

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.

Emery P; Genovese MC; van Vollenhoven R; Sharp JT; Patra K; Sasso EH
Article: ANNALS OF THE RHEUMATIC DISEASES. 2009;68(6):797-804

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.

Smolen J; Landewé RB; Mease P; Brzezicki J; Mason D; Luijtens K; van Vollenhoven RF; Kavanaugh A; Schiff M; Burmester GR; Strand V; Vencovsky J; van der Heijde D
Article: ANNALS OF THE RHEUMATIC DISEASES. 2009;68(6):805-811

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.

Fleischmann R; Vencovsky J; van Vollenhoven RF; Borenstein D; Box J; Coteur G; Goel N; Brezinschek H-P; Innes A; Strand V
Article: ANNALS OF THE RHEUMATIC DISEASES. 2009;68(5):648-653

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.

Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
Article: ANNALS OF THE RHEUMATIC DISEASES. 2009;68(4):456-459

Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.

Emery P; Van Vollenhoven R; Ostergaard M; Choy E; Combe B; Graninger W; Krueger K; Matucci-Cerinic M; Navarro F; van Riel P; Settas L; Steinfeld S
Article: ARTHRITIS RESEARCH & THERAPY. 2009;11(3):R76

Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis.

Hueber W; Tomooka BH; Batliwalla F; Li W; Monach PA; Tibshirani RJ; Van Vollenhoven RF; Lampa J; Saito K; Tanaka Y; Genovese MC; Klareskog L; Gregersen PK; Robinson WH
Article: ARTHRITIS RESEARCH & THERAPY. 2009;11(6):R170

Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.

Strand V; Mease P; Burmester GR; Nikaï E; Coteur G; van Vollenhoven R; Combe B; Keystone EC; Kavanaugh A
Article: ARTHRITIS & RHEUMATOLOGY. 2008;58(11):3319-3329

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Keystone E; Heijde DVD; Mason D; Landewé R; Vollenhoven RV; Combe B; Emery P; Strand V; Mease P; Desai C; Pavelka K
Article: ANNALS OF THE RHEUMATIC DISEASES. 2008;67(11):1516-1523

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.

Emery P; Keystone E; Tony HP; Cantagrel A; van Vollenhoven R; Sanchez A; Alecock E; Lee J; Kremer J
Article: ARTHRITIS & RHEUMATOLOGY. 2008;59(10):1371-1377

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.

Aletaha D; Landewe R; Karonitsch T; Bathon J; Boers M; Bombardier C; Bombardieri S; Choi H; Combe B; Dougados M; Emery P; Gomez-Reino J; Keystone E; Koch G; Kvien TK; Martin-Mola E; Matucci-Cerinic M; Michaud K; O'Dell J; Paulus H; Pincus T; Richards P; Simon L; Siegel J; Smolen JS; Sokka T; Strand V; Tugwell P; van der Heijde D; van Riel P; Vlad S; van Vollenhoven R; Ward M; Weinblatt M; Wells G; White B; Wolfe F; Zhang B; Zink A; Felson D; EULAR; ACR
Article: ANNALS OF THE RHEUMATIC DISEASES. 2008;67(10):1360-1364

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.

Aletaha D; Landewe R; Karonitsch T; Bathon J; Boers M; Bombardier C; Bombardieri S; Choi H; Combe B; Dougados M; Emery P; Gomez-Reino J; Keystone E; Koch G; Kvien TK; Martin-Mola E; Matucci-Cerinic M; Michaud K; O'Dell J; Paulus H; Pincus T; Richards P; Simon L; Siegel J; Smolen JS; Sokka T; Strand V; Tugwell P; van der Heijde D; van Riel P; Vlad S; van Vollenhoven R; Ward M; Weinblatt M; Wells G; White B; Wolfe F; Zhang B; Zink A; Felson D
Article: ANNALS OF THE RHEUMATIC DISEASES. 2008;67(9):1267-1270

Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial.

van der Heijde D; Landewé R; van Vollenhoven R; Fatenejad S; Klareskog L
Article: ARTHRITIS & RHEUMATOLOGY. 2008;58(6):1784-1788

Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index.

Petri M; Kasitanon N; Lee S-S; Link K; Magder L; Bae S-C; Hanly JG; Isenberg DA; Nived O; Sturfelt G; van Vollenhoven R; Wallace DJ; Alarcón GS; Adu D; Avila-Casado C; Bernatsky SR; Bruce IN; Clarke AE; Contreras G; Fine DM; Gladman DD; Gordon C; Kalunian KC; Madaio MP; Rovin BH; Sanchez-Guerrero J; Steinsson K; Aranow C; Balow JE; Buyon JP; Ginzler EM; Khamashta MA; Urowitz MB; Dooley MA; Merrill JT; Ramsey-Goldman R; Font J; Tumlin J; Stoll T; Zoma A; Systemic Lupus International Collaborating Clinics
Article: ARTHRITIS & RHEUMATOLOGY. 2008;58(6):1789-1795

Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response.

Petri M; Kasitanon N; Singh S; Link K; Magder L; Bae S-C; Hanly JG; Nived O; Sturfelt G; van Vollenhoven R; Wallace DJ; Alarcón GS; Adu D; Avila-Casado C; Bernatsky SR; Bruce IN; Clarke AE; Contreras G; Fine DM; Gladman DD; Gordon C; Kalunian KC; Madaio MP; Rovin BH; Sanchez-Guerrero J; Steinsson K; Aranow C; Balow JE; Buyon JP; Ginzler EM; Khamashta MA; Urowitz MB; Dooley MA; Merrill JT; Ramsey-Goldman R; Font J; Tumlin J; Stoll T; Zoma A; Systemic Lupus International Collaborating Clinics
Article: ARTHRITIS & RHEUMATOLOGY. 2008;59(5):721-729

Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study.

Hanly JG; Urowitz MB; Su L; Sanchez-Guerrero J; Bae SC; Gordon C; Wallace DJ; Isenberg D; Alarcón GS; Merrill JT; Clarke A; Bernatsky S; Dooley MA; Fortin PR; Gladman D; Steinsson K; Petri M; Bruce IN; Manzi S; Khamashta M; Zoma A; Font J; Van Vollenhoven R; Aranow C; Ginzler E; Nived O; Sturfelt G; Ramsey-Goldman R; Kalunian K; Douglas J; Qiufen Qi K; Thompson K; Farewell V; Systemic Lupus International Collaborating Clinics
Article: ANNALS OF THE RHEUMATIC DISEASES. 2008;67(3):330-334

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response.

Jónsdóttir T; Gunnarsson I; Risselada A; Henriksson EW; Klareskog L; van Vollenhoven RF
Article: ARTHRITIS & RHEUMATOLOGY. 2008;58(3):843-853

Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study.

Hanly JG; Urowitz MB; Siannis F; Farewell V; Gordon C; Bae SC; Isenberg D; Dooley MA; Clarke A; Bernatsky S; Gladman D; Fortin PR; Manzi S; Steinsson K; Bruce IN; Ginzler E; Aranow C; Wallace DJ; Ramsey-Goldman R; van Vollenhoven R; Sturfelt G; Nived O; Sanchez-Guerrero J; Alarcón GS; Petri M; Khamashta M; Zoma A; Font J; Kalunian K; Douglas J; Qi Q; Thompson K; Merrill JT; Systemic Lupus International Collaborating Clinics
Article: ARTHRITIS & RHEUMATOLOGY. 2008;59(2):176-180

Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort.

Urowitz MB; Gladman D; Ibañez D; Fortin P; Sanchez-Guerrero J; Bae S; Clarke A; Bernatsky S; Gordon C; Hanly J; Wallace D; Isenberg D; Ginzler E; Merrill J; Alarcón GS; Steinsson K; Petri M; Dooley MA; Bruce I; Manzi S; Khamashta M; Ramsey-Goldman R; Zoma A; Sturfelt G; Nived O; Maddison P; Font J; van Vollenhoven R; Aranow C; Kalunian K; Stoll T; Systemic Lupus International Collaborating Clinics
Article: ARTHRITIS & RHEUMATOLOGY. 2008;58(1):36-45

Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.

Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J
Article: ARTHRITIS & RHEUMATOLOGY. 2007;56(12):3896-3908

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.

Keystone E; Fleischmann R; Emery P; Furst DE; van Vollenhoven R; Bathon J; Dougados M; Baldassare A; Ferraccioli G; Chubick A; Udell J; Cravets MW; Agarwal S; Cooper S; Magrini F
Article: ANNALS OF THE RHEUMATIC DISEASES. 2007;66(11):1462-1466

Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis.

Augustsson J; Eksborg S; Ernestam S; Gullström E; van Vollenhoven R
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2007;36(6):418-423

Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE.

van Vollenhoven RF; Klareskog L
Article: ANNALS OF THE RHEUMATIC DISEASES. 2007;66(10):1339-1344

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.

Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven RF; Klareskog L
Article: ARTHRITIS & RHEUMATOLOGY. 2007;56(4):1263-1272

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.

Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
Article: ARTHRITIS RESEARCH & THERAPY. 2007;9(5):R87

Skewed distribution of proinflammatory CD4+CD28null T cells in rheumatoid arthritis.

Fasth AER; Snir O; Johansson AAT; Nordmark B; Rahbar A; Af Klint E; Björkström NK; Ulfgren A-K; van Vollenhoven RF; Malmström V; Trollmo C
Article: LUPUS. 2007;16(9):731-735

Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort.

Urowitz MB; Gladman D; Ibañez D; Fortin P; Sanchez-Guerrero J; Bae S; Clarke A; Bernatsky S; Gordon C; Hanly J; Wallace D; Isenberg D; Ginzler E; Merrill J; Alarcon G; Steinsson K; Petri M; Dooley MA; Bruce I; Manzi S; Khamashta M; Ramsey-Goldman R; Zoma A; Sturfelt G; Nived O; Maddison P; Font J; van Vollenhoven R; Aranow C; Kalunian K; Stoll T; Buyon J
Article: ARTHRITIS & RHEUMATOLOGY. 2007;56(1):265-273

Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study.

Hanly JG; Urowitz MB; Sanchez-Guerrero J; Bae SC; Gordon C; Wallace DJ; Isenberg D; Alarcón GS; Clarke A; Bernatsky S; Merrill JT; Petri M; Dooley MA; Gladman D; Fortin PR; Steinsson K; Bruce I; Manzi S; Khamashta M; Zoma A; Aranow C; Ginzler E; Van Vollenhoven R; Font J; Sturfelt G; Nived O; Ramsey-Goldman R; Kalunian K; Douglas J; Thompson K; Farewell V; Systemic Lupus International Collaborating Clinics
Article: CLINICAL IMMUNOLOGY. 2007;122(1):62-74

Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.

Vallerskog T; Gunnarsson I; Widhe M; Risselada A; Klareskog L; van Vollenhoven R; Malmström V; Trollmo C
Article: ARTHRITIS & RHEUMATOLOGY. 2006;54(10):3119-3125

Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes.

Landewé R; van der Heijde D; Klareskog L; van Vollenhoven R; Fatenejad S
Article: ARTHRITIS & RHEUMATOLOGY. 2006;54(5):1390-1400

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM; DANCER Study Group
Article: ARTHRITIS & RHEUMATOLOGY. 2006;54(1):26-37

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2005;34(5):353-358

Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.

Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2005;64(12):1744-1749

Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression.

Rönnelid J; Wick MC; Lampa J; Lindblad S; Nordmark B; Klareskog L; van Vollenhoven RF
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2005;23(5 Suppl 39):S195-S200

Rheumatoid arthritis registries in Sweden.

van Vollenhoven RF; Askling J
Article: ANNALS OF THE RHEUMATIC DISEASES. 2005;64(4):654

Feasibility of 1 hour infliximab infusions.

van Vollenhoven RF; Gullström E; Klareskog L
Article: ANNALS OF THE RHEUMATIC DISEASES. 2005;64(1):134-137

Estimated prediagnosis radiological progression: an important tool for studying the effects of early disease modifying antirheumatic drug treatment in rheumatoid arthritis.

Wick MC; Lindblad S; Weiss RJ; Klareskog L; van Vollenhoven RF
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2004;33(6):423-427

Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone.

van Vollenhoven RF; Gunnarsson I; Welin-Henriksson E; Sundelin B; Osterborg A; Jacobson SH; Klareskog L
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2004;33(6):380-384

Clinical and radiological disease-course in a Swedish DMARD-treated early RA-inception cohort: an observational study.

Wick MC; Lindblad S; Weiss RJ; Klareskog L; van Vollenhoven RF
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2004;22(5 Suppl 35):S122-S125

Benefits and risks of biological agents: lymphomas.

van Vollenhoven RF
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2004;22(5 Suppl 35):S115-S121

Switching between biological agents.

van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2004;63(9):1075-1078

Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.

Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2004;60(1-2):199-208

CD28nullCD4+ T cells--characterization of an effector memory T-cell population in patients with rheumatoid arthritis.

Fasth AER; Cao D; van Vollenhoven R; Trollmo C; Malmström V
Article: ANNALS OF THE RHEUMATIC DISEASES. 2004;63(7):848-852

Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description.

Wick MC; Lindblad S; Klareskog L; Van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2004;63(4):426-430

Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect.

van Vollenhoven RF; Brannemark S; Klareskog L
Article: ARTHRITIS RESEARCH & THERAPY. 2004;6(4):R335-R346

CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease.

Cao D; van Vollenhoven R; Klareskog L; Trollmo C; Malmström V
Article: ANNALS OF THE RHEUMATIC DISEASES. 2003;62(12):1195-1198

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense.

van Vollenhoven R; Harju A; Brannemark S; Klareskog L
Article: ARTHRITIS & RHEUMATOLOGY. 2003;48(6):1500-1503

Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry.

van Vollenhoven RF; Klareskog L
Article: JOURNAL OF RHEUMATOLOGY. 2003;30(3):449-454

Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial.

Kavanaugh A; Genovese M; Baughman J; Kivitz A; Bulpitt K; Olsen N; Weisman M; Matteson E; Furst D; van Vollenhoven R; Anderson J; Cohen S; Wei N; Meijerink J; Jacobs C; Mocci S
Article: ARTHRITIS RESEARCH & THERAPY. 2003;5(6):R347-R351

Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious.

van Vollenhoven RF; Ernestam S; Harju A; Bratt J; Klareskog L
Article: JOURNAL OF RHEUMATOLOGY. 2002;29(10):2114-2121

VH4-34 encoded antibody in systemic lupus erythematosus: effect of isotype.

Bhat NM; Lee LM; van Vollenhoven RF; Teng NNH; Bieber MM
Article: JOURNAL OF RHEUMATOLOGY. 2002;29(4):693-699

Repeated renal biopsy in proliferative lupus nephritis--predictive role of serum C1q and albuminuria.

Gunnarsson I; Sundelin B; Heimbürger M; Forslid J; van Vollenhoven R; Lundberg I; Jacobson SH
Article: ANNALS OF THE RHEUMATIC DISEASES. 2001;60(4):372-379

Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus.

Svenungsson E; Andersson M; Brundin L; van Vollenhoven R; Khademi M; Tarkowski A; Greitz D; Dahlström M; Lundberg I; Klareskog L; Olsson T
Article: ANNALS OF THE RHEUMATIC DISEASES. 2001;60(2):133-139

Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors.

Berg L; Lampa J; Rogberg S; van Vollenhoven R; Klareskog L
Article: RHEUMATIC DISEASE CLINICS OF NORTH AMERICA. 2000;26(2):349-362

Dehydroepiandrosterone in systemic lupus erythematosus.

van Vollenhoven RF
Article: JOURNAL OF RHEUMATOLOGY. 1999;26(10):2153-2158

Psychosocial correlates of morbidity in women with systemic lupus erythematosus.

Ward MM; Lotstein DS; Bush TM; Lambert RE; van Vollenhoven R; Neuwelt CM
Article: JOURNAL OF RHEUMATOLOGY. 1999;26(8):1727-1733

VH4-34 encoded antibodies in systemic lupus erythematosus: a specific diagnostic marker that correlates with clinical disease characteristics.

van Vollenhoven RF; Bieber MM; Powell MJ; Gupta PK; Bhat NM; Richards KL; Albano SA; Teng NN
Article: JCR-JOURNAL OF CLINICAL RHEUMATOLOGY. 1999;5(4):228-232

Treatment of severe CNS lupus with intravenous immunoglobulin.

Engel G; van Vollenhoven RF
Article: JCR-JOURNAL OF CLINICAL RHEUMATOLOGY. 1999;5(1):9-16

Influence of hormonal events on disease expression in patients with the combination of systemic lupus erythematosus and rheumatoid arthritis.

Sundaramurthy SG; Karsevar MP; van Vollenhoven RF
Article: JOURNAL OF RHEUMATOLOGY. 1999;26(1):197

Severe rheumatoid arthritis.

van Vollenhoven RF
Article: LUPUS. 1999;8(3):181-187

A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.

van Vollenhoven RF; Park JL; Genovese MC; West JP; McGuire JL
Article: JOURNAL OF RHEUMATOLOGY. 1998;25(12):2352-2356

Dehydroepiandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response.

Barry NN; McGuire JL; van Vollenhoven RF
Article: JOURNAL OF RHEUMATOLOGY. 1998;25(9):1720-1729

Socioeconomic status and health in women with systemic lupus erythematosus.

Lotstein DS; Ward MM; Bush TM; Lambert RE; van Vollenhoven R; Neuwelt CM
Article: JOURNAL OF RHEUMATOLOGY. 1998;25(2):285-289

Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.

van Vollenhoven RF; Morabito LM; Engleman EG; McGuire JL
Article: POSTGRADUATE MEDICINE. 1998;103(2):137-142

Corticosteroids in rheumatic disease. Understanding their effects is key to their use.

van Vollenhoven RF
Article: POSTGRADUATE MEDICINE. 1998;103(2):103-106

Rheumatoid arthritis. Designing and implementing a treatment plan.

Gremillion RB; van Vollenhoven RF
Article: AMERICAN JOURNAL OF MEDICINE. 1997;103(3):233-241

Skeletal status of men with early and late ankylosing spondylitis.

Lee YS; Schlotzhauer T; Ott SM; van Vollenhoven RF; Hunter J; Shapiro J; Marcus R; McGuire JL
Article: ANNALES DE MEDECINE INTERNE. 1996;147(4):290-296

Studies of dehydroepiandrosterone (DHEA) as a therapeutic agent in systemic lupus erythematosus.

Van Vollenhoven RF; McGuire JL
Article: ARTHRITIS & RHEUMATOLOGY. 1995;38(12):1826-1831

Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial.

van Vollenhoven RF; Engleman EG; McGuire JL
Visa fler

Alla övriga publikationer

Review: ANNALS OF THE RHEUMATIC DISEASES. 2020;79(6):685-699

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.

Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg J-E; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
Review: ANNALS OF THE RHEUMATIC DISEASES. 2020;79(6):713-723

2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.

Fanouriakis A; Kostopoulou M; Cheema K; Anders H-J; Aringer M; Bajema I; Boletis J; Frangou E; Houssiau FA; Hollis J; Karras A; Marchiori F; Marks SD; Moroni G; Mosca M; Parodis I; Praga M; Schneider M; Smolen JS; Tesar V; Trachana M; van Vollenhoven RF; Voskuyl AE; Teng YKO; van Leew B; Bertsias G; Jayne D; Boumpas DT
Review: ANNALS OF THE RHEUMATIC DISEASES. 2019;78(9):1160-1166

2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis.

Ehlers L; Askling J; Bijlsma HW; Cid MC; Cutolo M; Dasgupta B; Dejaco C; Dixon WG; Feltelius N; Finckh A; Gilbert K; Mackie SL; Mahr A; Matteson EL; Neill L; Salvarani C; Schmidt WA; Strangfeld A; van Vollenhoven RF; Buttgereit F
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2019;78(7):1010-1012

Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort.

Mendel A; Bernatsky SB; Hanly JG; Urowitz MB; Clarke AE; Romero-Diaz J; Gordon C; Bae S-C; Wallace DJ; Merrill JT; Buyon JP; Isenberg DA; Rahman A; Ginzler EM; Petri M; Dooley MA; Fortin PR; Gladman DD; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Mackay M; Alarcón GS; Manzi S; Nived O; Jönsen A; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim S; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Sanchez-Guerrero J; Bruce IN; Costedoat-Chalumeau N; Vinet É
Review: ANNALS OF THE RHEUMATIC DISEASES. 2019;78(6):736-745

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.

Fanouriakis A; Kostopoulou M; Alunno A; Aringer M; Bajema I; Boletis JN; Cervera R; Doria A; Gordon C; Govoni M; Houssiau F; Jayne D; Kouloumas M; Kuhn A; Larsen JL; Lerstrøm K; Moroni G; Mosca M; Schneider M; Smolen JS; Svenungsson E; Tesar V; Tincani A; Troldborg A; van Vollenhoven R; Wenzel J; Bertsias G; Boumpas DT
Review: NATURE REVIEWS RHEUMATOLOGY. 2018;14(2):75-93

Moving towards a molecular taxonomy of autoimmune rheumatic diseases.

Barturen G; Beretta L; Cervera R; Van Vollenhoven R; Alarcón-Riquelme ME
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):1102-1107

Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.

Chatzidionysiou K; Emamikia S; Nam J; Ramiro S; Smolen J; van der Heijde D; Dougados M; Bijlsma J; Burmester G; Scholte M; van Vollenhoven R; Landewé R
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):1101-1136

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.

Ramiro S; Sepriano A; Chatzidionysiou K; Nam JL; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; Bijlsma JW; Burmester GR; Scholte-Voshaar M; Falzon L; Landewé RBM
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):1113-1136

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.

Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewé R
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):960-977

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS; Landewé R; Bijlsma J; Burmester G; Chatzidionysiou K; Dougados M; Nam J; Ramiro S; Voshaar M; van Vollenhoven R; Aletaha D; Aringer M; Boers M; Buckley CD; Buttgereit F; Bykerk V; Cardiel M; Combe B; Cutolo M; van Eijk-Hustings Y; Emery P; Finckh A; Gabay C; Gomez-Reino J; Gossec L; Gottenberg J-E; Hazes JMW; Huizinga T; Jani M; Karateev D; Kouloumas M; Kvien T; Li Z; Mariette X; McInnes I; Mysler E; Nash P; Pavelka K; Poór G; Richez C; van Riel P; Rubbert-Roth A; Saag K; da Silva J; Stamm T; Takeuchi T; Westhovens R; de Wit M; van der Heijde D
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):948-959

2016 update of the EULAR recommendations for the management of early arthritis.

Combe B; Landewe R; Daien CI; Hua C; Aletaha D; Álvaro-Gracia JM; Bakkers M; Brodin N; Burmester GR; Codreanu C; Conway R; Dougados M; Emery P; Ferraccioli G; Fonseca J; Raza K; Silva-Fernández L; Smolen JS; Skingle D; Szekanecz Z; Kvien TK; van der Helm-van Mil A; van Vollenhoven R
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(10):e69

Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers.

Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; Heijde DVD; Vollenhoven RV; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
Letter: ARTHRITIS CARE & RESEARCH. 2016;68(7):1051

Reply.

Lesuis N; Piek E; Demirel H; den Broeder AA; Hulscher MEJL; Meek I; van der Laan-Baalbergen N; van Vollenhoven RF
Letter: ARTHRITIS CARE & RESEARCH. 2016;68(7):1053-1054

Reply.

Pope JE; Rothfield NF; Ramsey-Goldman R; Douglas Smith C; Bernatsky SR; Furie RA; Hudson M; Burgos-Vargas R; Senécal J-L; Inanç M; van Vollenhoven RF; Chandran V; Nash PT; Muangchan C
Corrigendum: ARTHRITIS RESEARCH & THERAPY. 2016;18(1):144

Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.

Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Ancuta I; Pavelka K; Nordström DC; Gabay C; Canhão H; Tomsic M; van Riel PLCM; Gomez-Reino J; Kvien TK; van Vollenhoven RF
Review: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(1):16-22

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update.

Stoffer MA; Schoels MM; Smolen JS; Aletaha D; Breedveld FC; Burmester G; Bykerk V; Dougados M; Emery P; Haraoui B; Gomez-Reino J; Kvien TK; Nash P; Navarro-Compán V; Scholte-Voshaar M; van Vollenhoven R; van der Heijde D; Stamm TA
Review: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(1):3-15

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Smolen JS; Breedveld FC; Burmester GR; Bykerk V; Dougados M; Emery P; Kvien TK; Navarro-Compán MV; Oliver S; Schoels M; Scholte-Voshaar M; Stamm T; Stoffer M; Takeuchi T; Aletaha D; Andreu JL; Aringer M; Bergman M; Betteridge N; Bijlsma H; Burkhardt H; Cardiel M; Combe B; Durez P; Fonseca JE; Gibofsky A; Gomez-Reino JJ; Graninger W; Hannonen P; Haraoui B; Kouloumas M; Landewe R; Martin-Mola E; Nash P; Ostergaard M; Östör A; Richards P; Sokka-Isler T; Thorne C; Tzioufas AG; van Vollenhoven R; de Wit M; van der Heijde D
Editorial comment: CLINICAL EPIDEMIOLOGY. 2016;8:361-362

Prevalence and comorbidity of relapsing polychondritis.

Ludvigsson JF; van Vollenhoven R
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(12):2260-2261

Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis.

van Herwaarden N; Bouman CAM; van der Maas A; van Vollenhoven RF; Bijlsma JW; van den Hoogen FHJ; den Broeder AA; van den Bemt BJF
Editorial comment: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(12):2103-2106

Remission in SLE: closing in on the target.

van Vollenhoven RF; Voskuyl A; Morand E; Aranow C
Review: ARTHRITIS RESEARCH & THERAPY. 2015;17(1):181

Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?

Nagy G; van Vollenhoven RF
Letter: LUPUS. 2015;24(6):648-649

DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184.

van Vollenhoven RF; Layton M; Kahl L; Schifano L; Hachulla E; Machado D; Staumont-Sallé D; Patel J; JAK115919 Study Team
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2014;73(11):e73

Response to: 'MBDA: what is it good for?' by Yazici et al.

van Vollenhoven R; Hambardzumyan K; Chernoff D; Bolce R
Review: COCHRANE DATABASE OF SYSTEMATIC REVIEWS. 2014;(9):CD010455

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JWJ; van Vollenhoven RF; van den Bemt BJF
Review: ANNALS OF THE RHEUMATIC DISEASES. 2014;73(6):958-967

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.

van Vollenhoven RF; Mosca M; Bertsias G; Isenberg D; Kuhn A; Lerstrøm K; Aringer M; Bootsma H; Boumpas D; Bruce IN; Cervera R; Clarke A; Costedoat-Chalumeau N; Czirják L; Derksen R; Dörner T; Gordon C; Graninger W; Houssiau F; Inanc M; Jacobsen S; Jayne D; Jedryka-Goral A; Levitsky A; Levy R; Mariette X; Morand E; Navarra S; Neumann I; Rahman A; Rovensky J; Smolen J; Vasconcelos C; Voskuyl A; Voss A; Zakharova H; Zoma A; Schneider M
Editorial comment: BMC MEDICINE. 2014;12:25

Early start and stop of biologics: has the time come?

van Vollenhoven RF; Nagy G; Tak PP
Letter: ARTHRITIS & RHEUMATOLOGY. 2014;66(2):480

Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Reply.

Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW
Review: F1000 PRIME REPORTS. 2014;6:31

Advances in the treatment of rheumatoid arthritis.

Vivar N; Van Vollenhoven RF
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2013;369(12):1174

Case 16-2013: A girl with irritability, hypersomnia, and somatic symptoms.

van Vollenhoven RF
Editorial comment: ANNALS OF THE RHEUMATIC DISEASES. 2013;72(9):1433-1435

Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples.

Combe B; van Vollenhoven R
Review: CURRENT OPINION IN RHEUMATOLOGY. 2013;25(5):606-615

Challenges and opportunities in SLE clinical trials.

van Vollenhoven RF
Editorial comment: NATURE REVIEWS RHEUMATOLOGY. 2013;9(9):510-512

Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?

van Vollenhoven RF; Chatzidionysiou K
Review: CURRENT OPINION IN RHEUMATOLOGY. 2013;25(3):391-397

Small molecular compounds in development for rheumatoid arthritis.

van Vollenhoven RF
Editorial comment: LUPUS. 2013;22(4):341

B-cell-directed therapies in systemic lupus erythematosus--where do we stand?

van Vollenhoven R
Editorial comment: NATURE REVIEWS RHEUMATOLOGY. 2013;9(2):70-72

Rheumatoid arthritis in 2012: Progress in RA genetics, pathology and therapy.

van Vollenhoven RF
Review: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(11):1771-1782

Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.

Bertsias GK; Tektonidou M; Amoura Z; Aringer M; Bajema I; Berden JHM; Boletis J; Cervera R; Dörner T; Doria A; Ferrario F; Floege J; Houssiau FA; Ioannidis JPA; Isenberg DA; Kallenberg CGM; Lightstone L; Marks SD; Martini A; Moroni G; Neumann I; Praga M; Schneider M; Starra A; Tesar V; Vasconcelos C; van Vollenhoven RF; Zakharova H; Haubitz M; Gordon C; Jayne D; Boumpas DT; European League Against Rheumatism and European Re
Review: AUTOIMMUNITY REVIEWS. 2012;11(8):563-567

Rituximab - shadow, illusion or light?

van Vollenhoven RF
Review: ANNALS OF MEDICINE. 2012;44(3):225-232

Biologicals for the treatment of systemic lupus erythematosus?

Gunnarsson I; van Vollenhoven RF
Review: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(6):909-920

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Buch MH; Smolen JS; Betteridge N; Breedveld FC; Burmester G; Dörner T; Ferraccioli G; Gottenberg J-E; Isaacs J; Kvien TK; Mariette X; Martin-Mola E; Pavelka K; Tak PP; van der Heijde D; van Vollenhoven RF; Emery P; Rituximab Consensus Expert Committee
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(6):1172-1173

Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense deposits.

Jónsdóttir T; Sundelin B; Welin Henriksson E; van Vollenhoven RF; Gunnarsson I
Review: JOURNAL OF INTERNAL MEDICINE. 2011;269(6):614-625

When to initiate and discontinue biologic treatments for rheumatoid arthritis?

Chatzidionysiou K; van Vollenhoven RF
Review: NATURE REVIEWS RHEUMATOLOGY. 2011;7(4):205-215

Unresolved issues in biologic therapy for rheumatoid arthritis.

van Vollenhoven RF
Editorial comment: ARTHRITIS & RHEUMATOLOGY. 2011;63(3):594-596

More or less rituximab? Biology and clinic, regulators and researchers.

van Vollenhoven RF
Review: CLINICAL RHEUMATOLOGY. 2011;30 Suppl 1:S19-S24

Observational studies: a valuable source for data on the true value of RA therapies.

van Vollenhoven RF; Severens JL
Editorial comment: CLINICAL RHEUMATOLOGY. 2011;30:S1-S2

Introduction

van Vollenhoven RF; Severens JL
Review: ANNALS OF THE RHEUMATIC DISEASES. 2010;69(12):2074-2082

EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs.

Bertsias GK; Ioannidis JPA; Aringer M; Bollen E; Bombardieri S; Bruce IN; Cervera R; Dalakas M; Doria A; Hanly JG; Huizinga TWJ; Isenberg D; Kallenberg C; Piette JC; Schneider M; Scolding N; Smolen J; Stara A; Tassiulas I; Tektonidou M; Tincani A; van Buchem MA; van Vollenhoven R; Ward M; Gordon C; Boumpas DT
Review: ANNALS OF THE RHEUMATIC DISEASES. 2010;69(7):1269-1274

European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies.

Mosca M; Tani C; Aringer M; Bombardieri S; Boumpas D; Brey R; Cervera R; Doria A; Jayne D; Khamashta MA; Kuhn A; Gordon C; Petri M; Rekvig OP; Schneider M; Sherer Y; Shoenfeld Y; Smolen JS; Talarico R; Tincani A; van Vollenhoven RF; Ward MM; Werth VP; Carmona L
Review: ANNALS OF THE RHEUMATIC DISEASES. 2010;69(6):976-986

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

Nam JL; Winthrop KL; van Vollenhoven RF; Pavelka K; Valesini G; Hensor EMA; Worthy G; Landewé R; Smolen JS; Emery P; Buch MH
Review: ANNALS OF THE RHEUMATIC DISEASES. 2010;69(6):964-975

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Smolen JS; Landewé R; Breedveld FC; Dougados M; Emery P; Gaujoux-Viala C; Gorter S; Knevel R; Nam J; Schoels M; Aletaha D; Buch M; Gossec L; Huizinga T; Bijlsma JWJW; Burmester G; Combe B; Cutolo M; Gabay C; Gomez-Reino J; Kouloumas M; Kvien TK; Martin-Mola E; McInnes I; Pavelka K; van Riel P; Scholte M; Scott DL; Sokka T; Valesini G; van Vollenhoven R; Winthrop KL; Wong J; Zink A; van der Heijde D
Review: NATURE REVIEWS RHEUMATOLOGY. 2009;5(10):531-541

Treatment of rheumatoid arthritis: state of the art 2009.

van Vollenhoven RF
Editorial comment: ANNALS OF THE RHEUMATIC DISEASES. 2009;68(8):1237-1239

How to dose infliximab in rheumatoid arthritis: new data on a serious issue.

van Vollenhoven RF
Review: ANNALS OF THE RHEUMATIC DISEASES. 2009;68(4):477-483

EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints.

Bertsias GK; Ioannidis JPA; Boletis J; Bombardieri S; Cervera R; Dostal C; Font J; Gilboe IM; Houssiau F; Huizinga T; Isenberg D; Kallenberg CGM; Khamashta M; Piette JC; Schneider M; Smolen J; Sturfelt G; Tincani A; van Vollenhoven R; Boumpas DT; Gordon C
Review: ANNALS OF THE RHEUMATIC DISEASES. 2009;68(4):470-476

EULAR points to consider for conducting clinical trials in systemic lupus erythematosus.

Gordon C; Bertsias G; Ioannidis JPA; Boletis J; Bombardieri S; Cervera R; Dostál C; Font J; Gilboe I-M; Houssiau F; Huizinga TWJ; Isenberg D; Kallenberg CGM; Khamashta MA; Piette J-C; Schneider M; Smolen JS; Sturfelt G; Tincani A; Van Vollenhoven R; Boumpas DT
Editorial comment: BMC MEDICINE. 2009;7:12

Sex differences in rheumatoid arthritis: more than meets the eye..

van Vollenhoven RF
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2008;67(10):1493-1494

Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases.

Lu TY-T; Jónsdóttir T; van Vollenhoven RF; Isenberg DA
Review: ANNALS OF THE RHEUMATIC DISEASES. 2008;67(10):1365-1373

Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis.

Karonitsch T; Aletaha D; Boers M; Bombardieri S; Combe B; Dougados M; Emery P; Felson D; Gomez-Reino J; Keystone E; Kvien TK; Martin-Mola E; Matucci-Cerinic M; Richards P; van Riel P; Siegel J; Smolen JS; Sokka T; van der Heijde D; van Vollenhoven R; Ward M; Wells G; Zink A; Landewe R
Letter: RHEUMATOLOGY. 2008;47(7):1106-1107

Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.

van Vollenhoven RF; British Society for Rheumatology Biologics Registr
Published paper: LUPUS. 2008;17(5):447-449

The Janus of lupus--benefits and risks with B-cell therapy.

van Vollenhoven RF
Review: RHEUMATOLOGY. 2008;47(4):392-398

Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis.

Emery P; McInnes IB; van Vollenhoven R; Kraan MC
Review: ANNALS OF THE RHEUMATIC DISEASES. 2008;67(2):195-205

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.

Bertsias G; Ioannidis JPA; Boletis J; Bombardieri S; Cervera R; Dostal C; Font J; Gilboe IM; Houssiau F; Huizinga T; Isenberg D; Kallenberg CGM; Khamashta M; Piette JC; Schneider M; Smolen J; Sturfelt G; Tincani A; van Vollenhoven R; Gordon C; Boumpas DT; Task Force of the EULAR Standing Committee for Int
Letter: ARTHRITIS & RHEUMATOLOGY. 2008;58(2):634

CD20 epitope masking by rituximab:: comment on the article by Gunnarsson et al -: Reply

Gunnarsson I; Jonsdottir T; van Vollenhoven RF
Editorial comment: ARTHRITIS RESEARCH & THERAPY. 2008;10(2):105

Rheumatologists, take heart! We may be doing something right.

van Vollenhoven RF
Editorial comment: ANNALS OF THE RHEUMATIC DISEASES. 2007;66(7):849-851

Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue.

van Vollenhoven RF
Editorial comment: JOURNAL OF RHEUMATOLOGY. 2006;33(12):2372-2375

Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials.

Pincus T; Yazici Y; van Vollenhoven R
Letter: NEPHROLOGY DIALYSIS TRANSPLANTATION. 2006;21(6):1742-1743

Rituximab-induced long-term remission of membranous lupus nephritis.

Jacobson SH; van Vollenhoven R; Gunnarsson I
Review: ANNALS OF THE RHEUMATIC DISEASES. 2006;65(6):707-712

Swedish registers to examine drug safety and clinical issues in RA.

Askling J; Fored CM; Geborek P; Jacobsson LTH; van Vollenhoven R; Feltelius N; Lindblad S; Klareskog L
Letter: ARTHRITIS & RHEUMATOLOGY. 2005;52(12):4050-4051

In lupus nephritis, the benefit of rituximab monotherapy, as opposed to rituximab plus cyclophosphamide combination therapy, remains uncertain: comment on the article by Sfikakis et al.

van Vollenhoven R; Gunnarsson I
Letter: ARTHRITIS & RHEUMATOLOGY. 2005;53(4):626

Dehydroepiandrosterone versus placebo for Sjögren's syndrome: comment on the article by Pillemer et al.

van Vollenhoven R
Editorial comment: ARTHRITIS & RHEUMATOLOGY. 2005;52(4):991-994

The treatment of rheumatoid arthritis: getting better all the time?

van Vollenhoven RF; Klareskog L
Published paper: ARTHRITIS & RHEUMATOLOGY. 2004;50(9):2858-2868

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.

Petri MA; Mease PJ; Merrill JT; Lahita RG; Iannini MJ; Yocum DE; Ginzler EM; Katz RS; Gluck OS; Genovese MC; Van Vollenhoven R; Kalunian KC; Manzi S; Greenwald MW; Buyon JP; Olsen NJ; Schiff MH; Kavanaugh AF; Caldwell JR; Ramsey-Goldman R; St Clair EW; Goldman AL; Egan RM; Polisson RP; Moder KG; Rothfield NF; Spencer RT; Hobbs K; Fessler BJ; Calabrese LH; Moreland LW; Cohen SB; Quarles BJ; Strand V; Gurwith M; Schwartz KE
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2004;63(5):608

Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? Reply

van Vollenhoven RF
Published paper: ARTHRITIS & RHEUMATOLOGY. 2002;46(7):1820-1829

Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.

Petri MA; Lahita RG; Van Vollenhoven RF; Merrill JT; Schiff M; Ginzler EM; Strand V; Kunz A; Gorelick KJ; Schwartz KE; GL601 Study Group
Review: EXPERT OPINION ON PHARMACOTHERAPY. 2002;3(1):23-31

Dehydroepiandrosterone for the treatment of systemic lupus erythematosus.

van Vollenhoven RF
Review: LAKARTIDNINGEN. 2001;98(8):828-831

[Blockade of TNFalpha--new therapeutic principle in severe rheumatoid arthritis].

Larsson P; Bratt J; Harju A; van Vollenhoven R; Klareskog L
Letter: RHEUMATOLOGY. 2000;39(8):929-930

Dehydroepiandrosterone in the treatment of systemic lupus erythematosus.

van Vollenhoven RF
Letter: ARTHRITIS & RHEUMATOLOGY. 1998;41(10):1897-1898

Role of sex steroids in the Th1/Th2 cytokine balance: comment on the article by Miossec and van den Berg.

van Vollenhoven RF
Editorial comment: POSTGRADUATE MEDICINE. 1998;103(2):67

Rheumatology in primary care - A five-article symposium

van Vollenhoven RF
Review: ANNALES DE MEDECINE INTERNE. 1996;147(4):265-273

Systemic lupus erythematosus and pregnancy.

Druzin ML; Van Vollenhoven RF
Editorial comment: ANNALES DE MEDECINE INTERNE. 1996;147(4):239-240

Hormones and systemic lupus erythematosus

VanVollenhoven RF
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 1995;333(21):1424

Breast implants and connective-tissue diseases.

van Vollenhoven R
Visa fler

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI